Procoagulant antibodies
By combining bispecific procoagulant antibodies with coagulation factors IXa and X, enhancing enzyme activity, it solves the coagulation disorder caused by the deficiency of coagulation factor VIII in patients with hemophilia type A, providing a safe and convenient alternative therapy, significantly reducing the risk of bleeding .
Patent Information
- Application Number
- CN202411089893.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2018-01-31
- Filing Date
- 2018-02-01
- Publication Date
- 2024-11-15
AI Technical Summary
Patients with hemophilia type A lack of coagulation factor VIII or the presence of inhibitors, resulting in clotting process disorders. The existing alternative therapies are inconvenient and risk of antibody neutralization, and cannot effectively prevent bleeding.
A bispecific procoagulant antibody is developed that can bind to coagulation factor IXa and coagulation factor X to enhance its enzymatic activity, thereby replacing the lack of coagulation factor VIII and promoting the coagulation process.
Effectively restore the coagulation function of patients lacking coagulation factor VIII, reduce the risk of bleeding, and provide a more convenient and safe treatment plan suitable for patients with hemophilia A with inhibitors.
Smart Images

Figure CN118955719A_ABST
Abstract
Description
[0001] This application is a divisional application. The application date of the original application is February 1, 2018, the application number is 201880009891.3 (PCT / EP2018 / 052550), and the name of the invention is “Procoagulant Antibody”.
[0002] Incorporation by Reference of Sequence Listing
[0003] The sequence listing entitled "160163WO02_ST25" is 198 kilobytes, was created on January 30, 2018, and is incorporated herein by reference. Background Art
[0004] In patients with coagulopathy, such as in people with hemophilia A and B, various steps of the coagulation cascade become dysfunctional due to, for example, a lack or insufficient presence of functional coagulation factors. This dysfunction of a part of the coagulation cascade results in inadequate blood clotting and potentially life-threatening bleeding, or damage to internal organs such as joints.
[0005] Factor VIII (FVIII) deficiency, commonly known as hemophilia A, is a congenital bleeding disorder that affects approximately 420,000 people worldwide, of whom approximately 105,000 are currently diagnosed.
[0006] Patients with hemophilia A can receive coagulation factor replacement therapy, such as exogenous FVIII. Conventional treatment consists of replacement therapy, which is provided as prophylaxis or on-demand treatment of bleeding episodes. Until recently, prophylactic treatment for patients with severe hemophilia A was intravenous injections of plasma-derived FVIII or recombinant FVIII or its long-acting variants up to three times a week.
[0007] However, such patients have the risk of generating neutralizing antibodies (so-called "inhibitors") to such exogenous factors, thereby rendering previously effective therapies ineffective. Patients with hemophilia A with inhibitors are non-limiting examples of partially congenital, partially acquired coagulopathy. Patients who have already generated FVIII inhibitors cannot be treated with conventional replacement therapies. Recently, a new drug, Hemlibra, has been approved for subcutaneous prophylactic treatment of hemophilia A with inhibitors. Exogenous coagulation factors can only be administered intravenously, which is quite inconvenient and uncomfortable for patients. For example, infants and young children may have to have an intravenous catheter surgically inserted into a chest vein to ensure venous access. This puts them at great risk of developing bacterial infections. Therefore, even with Hemlibra, hemophilia with inhibitors requires alternative subcutaneous treatment.
[0008] In bleeding individuals, when extravascular TF is exposed to activated FVII (FVIIa) in the blood, coagulation is initiated by forming a tissue factor / factor VIIa (TF / VIIa) complex. The formation of the TF / VIIa complex causes coagulation factor X (FX) to be activated as activated coagulation factor Xa (FXa), which, together with activated coagulation factor V (FVa), produces a limited amount of thrombin, which in turn activates platelets. Activated platelets support the assembly of the tenase complex composed of activated factor VIII (FVIIIa) and activated coagulation factor IX (FIXa). The tenase complex is a very effective catalyst for FX activation, and the FXa generated in this second step serves as an active protease in the FVa / FXa prothrombinase complex, which is responsible for the final thrombin burst. Thrombin cleaves fibrinogen to generate fibrin monomers, which polymerize to form a fibrin mesh that seals leaking blood vessels and stops bleeding. A rapid and extensive thrombin burst is a prerequisite for the formation of a solid and stable fibrin clot.
[0009] Insufficient FXa formation and decreased thrombin generation caused by reduced or absent FVIII activity are the underlying causes of the bleeding diathesis in patients with hemophilia A.
[0010] As mentioned above, the proteolytic conversion of FX to its enzymatically active form FXa can be achieved by an intrinsic FX activation complex comprising FIXa and its cofactor FVIIIa. Cofactor binding increases the enzymatic activity of FIXa by about five orders of magnitude, and it is believed to occur through a variety of mechanisms outlined by Scheiflinger et al. (2008) J Thromb Haemost, 6:315-322. It is worth noting that FVIIIa has been found to stabilize the conformation of FIXa, and FIXa has increased proteolytic activity to FX (Kolkman JA, Mertens K (2000) Biochemistry, 39:7398-7405, T, Brandstetter H (2009) Biol Chem, 390: 391-400). Based on this observation and realizing that antibodies are universal binding proteins that can mimic a variety of protein-protein interactions, Scheiflinger et al. screened for agonistic anti-FIXa antibodies, which are characterized by the ability to enhance FIXa activation of FX in the presence of phospholipid surfaces and calcium, but in the absence of the natural cofactor FVIIIa. From the screening of 5280 hybridoma supernatants, 88 were found to produce antibodies that exhibited varying degrees of FIXa agonistic activity, see EP1220923B1 and EP1660536B1. Regarding the kinetics of FX activation and the ability to stimulate thrombin generation in human plasma lacking FVIII, EP1660536B1 consistently pointed out that 224F3 is the most effective antibody (see, for example, sections 0060 and 0062).
[0011] ACE910 or Emicizumab (trade name ) is a humanized bispecific anti-FIX(a) / anti-FX(a) monoclonal antibody developed by Chugai Pharmaceutical for the treatment of hemophilia A. ACE910 is designed to mimic FVIII cofactor function (see Sampei et al.: (2013) PLoS One, 8, e57479 and WO2012067176).
[0012] There remain many unmet medical needs in subjects suffering from coagulopathy in general, and in the hemophilia population in particular, and the present invention is directed to improved compounds that are able to replace FVIII and are therefore useful in treating coagulopathy such as hemophilia A. Summary of the invention
[0013] The present invention relates to compounds which act as replacements for coagulation factor VIII (FVIII) in patients suffering from coagulopathy, in particular patients lacking functional FVIII, such as hemophilia A patients, including hemophilia A patients with inhibitors.
[0014] Thus, one aspect of the present invention relates to compounds capable of enhancing the production of FXa and thus partially or fully restoring coagulation in patients deficient in FVIII.
[0015] In one aspect, the compound is an antibody. In one such aspect, the compound is a multispecific antibody, such as a bispecific antibody.
[0016] In a specific aspect, the invention relates to procoagulant antibodies that serve as replacements for FVIII in patients deficient in FVIII, such as hemophilia A patients.
[0017] In one such aspect, the antibody binds to and increases the enzymatic activity of FIXa towards FX, optionally also binds FX.
[0018] In one aspect, the invention relates to procoagulant antibodies that bind to FX, including bispecific procoagulant antibodies that increase the enzymatic activity of FIXa on FX and bind to FX.
[0019] In one aspect, the present invention relates to procoagulant bispecific antibodies capable of binding to coagulation FIX / FIXa and FX / FXa.
[0020] In one aspect, the antibody is a human antibody or a humanized antibody.
[0021] Another aspect of the invention relates to a separate antibody or antigen binding fragment thereof as part of a procoagulant antibody, such as a specific anti-FIX or anti-FIXa antibody or antigen binding fragment thereof. Another aspect of the invention relates to a separate antibody or antigen binding fragment thereof as part of a procoagulant antibody, such as a specific anti-FX or anti-FXa antibody or antigen binding fragment thereof.
[0022] Another aspect of the present invention relates to the preparation of antibodies and intermediates thereof as disclosed herein.
[0023] Another aspect of the invention relates to antibodies that compete for binding to FIX / FIXa with the procoagulant antibodies or antigen-binding fragments thereof disclosed herein.
[0024] Another aspect of the invention relates to procoagulant antibodies that compete with the antibodies or antigen-binding fragments thereof disclosed herein for binding to FX / FXa.
[0025] Yet another aspect of the present invention relates to a pharmaceutical composition comprising the procoagulant antibodies disclosed herein, formulated for delivery of said antibodies for the prevention and / or treatment of coagulopathy.
[0026] Another aspect of the present invention relates to the procoagulant antibodies disclosed herein for use in preventing and / or treating coagulopathy, diseases associated with coagulopathy or diseases caused by coagulopathy.
[0027] The present invention can also solve other problems that are apparent from the disclosure of the exemplary embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 An aligned sequence of SEQ ID NO: 3-188 is shown, wherein the complementarity determining regions 1, 2 and 3 (CDR1, CDR2 and CDR3) of the heavy and light chain variable domains have been highlighted consecutively in boxes.
[0029] Figure 2The thrombin generation test (TGT) data of bispecific antibodies mAb4-7761, mAb4-7762, mAb4-7789, mAb5-0057, mAb5-1409 and ACE910 in human tissue factor activated hemophilia A platelet-poor plasma (HA-PPP) are shown. The experiment is carried out as described in Example 17. Dotted and dashed lines represent the peak thrombin levels (nM) observed when there is no anti-FVIII antibody in HA-PPP and normal PPP, respectively, and their standard deviation is represented by dotted lines. The curves of mAb4-7761, mAb4-7762, mAb4-7789, mAb5-0057 and mAb5-1409 are represented by upward pointing triangles, while the curve of ACE910 is represented by downward pointing triangles. Experiments AD refer to independent experiments; In each of these experiments, the peak thrombin levels at each antibody concentration represent the mean ± standard deviation of at least three independent runs.
[0030] Figure 3 The thrombin generation test (TGT) data of bispecific antibodies mAb5-0057, mAb5-1409 and ACE910 in human tissue factor activated hemophilia A platelet-rich plasma (HA-PRP) are shown. The experiment is carried out as described in Example 17. Dotted and dashed lines represent the peak thrombin levels (nM) observed when there is no anti-FVIII antibody in HA-PRP and normal PRP, respectively, and their standard deviation is represented by dotted lines. The curves of mAb5-0057 and mAb5-1409 are represented by upward pointing triangles, while the curve of ACE910 is represented by downward pointing triangles. The results are shown as mean ± standard deviation from four independent experiments.
[0031] Figure 4 The thrombin generation test (TGT) data of monovalent one-arm (OA) antibodies of mAb1-9016 and 224F3 in platelet-poor plasma activated by human factor Xla are shown. The experiment is performed as described in Example 18. The dotted line represents the average peak thrombin level (nM) observed in the absence of antibody, and its standard deviation (± 1SD) is represented by a dotted line. The curves of the OA forms of mAb1-9016 and 224F3 (mAb1-1582) are represented by triangles pointing upward and downward, respectively.
[0032] Sequence Description
[0033] SEQ ID NO: 1 is the amino acid sequence of human coagulation factor IX.
[0034] SEQ ID NO: 2 is the amino acid sequence of human coagulation factor X.
[0035] SEQ ID NO: 3-188 are heavy chain variable domains (V H ) and the light chain variable domain (V L ) sequences. The corresponding one-armed (OA) antibodies and the IDs of some bispecific antibodies are also shown in the table. Figure 1 In the figure, the CDR1-3 sequences are highlighted in the box.
[0036] Corresponding V H and V L Summary of antibody abbreviations, targets and SEQ ID NOs:
[0037]
[0038]
[0039]
[0040]
[0041] The first column ("OA or bispecific antibody ID") contains the abbreviations of the monovalent one-armed (OA) antibody and / or the bispecific antibody. The second column ("mAb ID") represents the abbreviations of the corresponding component antibodies (for bispecific antibodies, the first antibody mentioned in the second column is the anti-FIX / FIXa antibody and the second is the anti-FX / FXa antibody). The fourth column ("SEQ ID NO (V H )”) and the fifth column (“SEQ ID NO(V L )”) represent V H and V L SEQ ID NOs of the sequences, wherein the first SEQ ID NO in each column represents an anti-FIX / FIXa antibody and the second represents an anti-FX / FXa antibody.
[0042] describe
[0043] In subjects suffering from coagulopathy, such as in people suffering from hemophilia A, due to the lack or insufficient presence of functional FVIII, the coagulation cascade becomes dysfunctional. This dysfunction of a part of the coagulation cascade leads to insufficient blood coagulation and potentially life-threatening bleeding, or damage to internal organs such as joints. The present invention relates to compounds, which serve as a substitute for coagulation factor VIII (FVIII) in patients suffering from coagulopathy, particularly patients lacking functional FVIII, such as hemophilia A patients, including hemophilia A patients with inhibitors. In one aspect, such a compound is an antibody.
[0044] In particular, the inventors of the present invention have surprisingly identified antibodies that mimic the activity of the FVIII cofactor with high potency and efficacy.
[0045] In a specific aspect, the invention relates to procoagulant antibodies that serve as replacements for FVIII in patients lacking functional FVIII, such as hemophilia A patients.
[0046] In one such aspect, the procoagulant antibody binds to and increases the enzymatic activity of coagulation factor IXa (FIXa) on coagulation factor X (FX), optionally also binds FX. In one such aspect, the antibody of the invention is a bispecific antibody capable of binding to FIX / FIXa and FX.
[0047] Coagulation Factor IX
[0048] FIX is a vitamin K dependent coagulation factor with structural similarity to factor VII, prothrombin, factor X and protein C. The circulating zymogen form is composed of 415 amino acids divided into four different domains, and these four domains include the domain rich in gamma-carboxyglutamic acid (Gla) at the N-terminus, two EGF domains and C-terminal trypsin-like serine protease domains. FIX circulates in blood plasma as a single-chain zymogen (SEQ ID NO:1). The activation peptide (residues 146 to 180 of SEQ ID NO:1) is released by limited proteolysis at Arg145 and Arg180, and activation of FIX occurs. Therefore, activated FIX (FIXa) is composed of residues 1-145 (light chain) of SEQ ID NO:1 and residues 181-415 (heavy chain) of SEQ ID NO:1.
[0049] Thus, circulating FIX molecules include FIX zymogens and activated forms of FIX, which are generally referred to herein as FIX and FIXa with reference to SEQ ID NO: 1. Activated factor IX is referred to as factor IXa or FIXa. The term "FIX (SEQ ID NO: 1) and / or its activated form (FIXa)" may also be referred to as "FIX / FIXa" or "FIX(a)".
[0050] FIXa is a trypsin-like serine protease that plays a key role in hemostasis by generating the majority of factor Xa necessary to support the formation of proper thrombin during the coagulation process as part of the tenase complex.
[0051] FIX is represented herein by SEQ ID NO: 1, which corresponds to the Ala148 allele form of human FIX (Anson et al. EMBO J. 19843: 1053-1060; McGraw et al., Proc Natl Acad Sci USA. 198582: 2847-2851; Graham et al. Am. J. Hum. Genet. 198842: 573-580). In the present invention, FIX is intended to encompass all natural variants of FIX, such as the T148 variant (Uniprot ID P00740).
[0052] Coagulation Factor X
[0053] FX is a vitamin K-dependent coagulation factor with structural similarity to factor VII, prothrombin, FIX and protein C. Human FX proenzyme contains four different domains, including a domain rich in gamma-carboxyglutamic acid (Gla) at the N-terminus, two EGF domains and a C-terminal trypsin-like serine protease domain. FX circulates in plasma as a two-chain proenzyme, which contains residues 1-139 (light chain) of SEQ ID NO:2 and residues 143-448 (heavy chain) of SEQ ID NO:2. FX activation occurs by limited proteolysis at Arg194, which results in the release of the activation peptide (Aa143-194). Therefore, activated FX (FXa) is composed of residues 1-139 (light chain) of SEQ ID NO:2 and residues 195-448 (activated heavy chain) of SEQ ID NO:2. Therefore, circulating FX molecules contain FX proenzyme and activated form of FX, which are referred to as FX and FXa herein, respectively, with reference to SEQ ID NO:2. In the present invention, FX is intended to encompass all natural variants of FX. The term "FX (SEQ ID NO: 2) and / or its activated form (FXa)" may also be referred to as "FX / FXa" or "FX(a)".
[0054] Antibody
[0055] The term "antibody" herein refers to a protein derived from an immunoglobulin sequence that is capable of binding to an antigen or a portion thereof. The term antibody includes, but is not limited to, full-length antibodies of any class (or isotype), i.e., IgA, IgD, IgE, IgG, IgM, and / or IgY. The term antibody includes, but is not limited to, bivalent antibodies, such as bispecific antibodies.
[0056] A natural full-length antibody comprises at least four polypeptide chains: two heavy chains (HC) and two light chains (LC) connected by disulfide bonds. In some cases, natural antibodies comprise less than four chains, such as the case of IgNAR found in cartilaginous fish (Chondrichthyes). One class of immunoglobulins of particular interest pharmaceutically is IgG. In humans, the IgG class can be divided into four subclasses: IgG1, IgG2, IgG3 and IgG4, based on the sequence of its heavy chain constant region. Light chains can be divided into two types, κ and λ chains, based on differences in their sequence composition. An IgG molecule consists of two heavy chains interconnected by two or more disulfide bonds and two light chains, each of which is connected to a heavy chain by a disulfide bond. An IgG heavy chain may comprise a heavy chain variable domain (V H ) and up to three heavy chain constant (C H ) Domain: C H 1. C H 2 and C H 3. The light chain may include a light chain variable domain (V L ) and the light chain constant domain (C L ). H and V L The V regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR) or hypervariable regions (HvR), interspersed with regions that are more conserved, termed framework regions (FR). H and V L The domain is usually composed of three CDRs and four FRs, which are arranged from amino terminus to carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The heavy and light chain variable domains (CDRs) containing the hypervariable regions constitute a structure capable of interacting with antigens, while the constant region of the antibody can mediate the binding of immunoglobulins to host tissues or factors, including but not limited to various cells of the immune system (effector cells), Fc receptors, and the first component of the C1 complex of the classical complement system, C1q.
[0057] The antibodies of the present invention can be monoclonal antibodies (mAbs), which are in the sense that they represent a unique set of heavy and light chain variable domain sequences expressed by a single B cell or by a clonal population of B cells. The antibodies of the present invention can be produced and purified using various methods known to those skilled in the art. For example, antibodies can be produced from hybridoma cells. Antibodies can be produced by B cell expansion. Antibodies or fragments thereof can be recombinantly expressed in mammalian or microbial expression systems or by in vitro translation. Antibodies or fragments thereof can also be recombinantly expressed as cell surface binding molecules by, for example, phage display, bacterial display, yeast display, mammalian cell display, or ribosome or mRNA display.
[0058] The antibodies of the present invention may be isolated. The term "isolated antibody" refers to an antibody that has been separated and / or recovered from other components of the environment in which it was produced, and / or an antibody that has been purified from a mixture of components present in the environment in which it was produced.
[0059] Certain antigen-binding fragments of antibodies may be suitable in the context of the present invention, as it has been demonstrated that the antigen-binding function of an antibody can be performed by fragments of a full-length antibody. The term "antigen-binding fragment" of an antibody refers to one or more antibody fragments that retain the ability to specifically bind or recognize an antigen such as FIX / FIXa, FX / FXa or another target molecule as described herein. Examples of antigen-binding fragments include, but are not limited to, Fab, Fab', Fab 2 Fab' 2 , Fv (usually the V L and V H domains), single-chain Fv (scFv); see, e.g., Bird et al., Science 1988 242:423-426; and Huston et al. PNAS 1988 85:5879-5883), dsFv, Fd (generally V H and C H 1 domain); contains a single V H and a single V L The invention relates to monovalent molecules of the present invention, such as minibodies, diabodies, triabodies, tetrabodies and kappa bodies (see, e.g., Ill et al. (1997) Protein Eng 10:949-57); and one or more isolated CDRs or functional paratopes, wherein the isolated CDRs or antigen binding residues or polypeptides can be associated or linked together to form functional antibody fragments. These antibody fragments can be obtained using conventional techniques known to those skilled in the art, and these fragments can be screened for applicability in the same manner as intact antibodies.
[0060] The "Fab fragment" of an antibody includes "Fab" and "Fab' 2 "Fab" fragments can be obtained from antibodies by cleaving the heavy chain in the hinge region on the N-terminal or C-terminal side of the hinge cysteine residues attached to the antibody heavy chain, respectively. The "Fab" fragment includes the variable and constant domains of the light chain and the variable and C-terminal domains of the heavy chain. H 1 domain. "Fab' 2 The "Fab" fragment contains a pair of "Fab" fragments that are usually covalently linked by their hinge cysteines. The Fab' 2 The hinge disulfide bond connecting the heavy chains in the Fab' 2Fragments. Other chemical couplings besides disulfide bonding of antibody fragments are also known in the art. Fab fragments retain the ability of the parent antibody to bind to its antigen, potentially with lower affinity. Fab' 2 Fab fragments are capable of bivalent binding, whereas Fab and Fab' fragments are capable of only monovalent binding. Typically, Fab fragments lack the constant C H 2 and C H The Fab fragment generally lacks effector functions. The Fab fragment can be produced by enzymatic cleavage of antibodies by methods known in the art, such as using papain to obtain Fab or using pepsin to obtain Fab'. 2 , including Fab, Fab', Fab' 2 Fab fragments including these can be produced recombinantly using techniques well known to those skilled in the art.
[0061] "Fv" (fragment variable) fragments are antibody fragments that contain complete antigen recognition and binding sites, and generally comprise one heavy chain variable domain and one light chain variable domain associated (which may be covalent in nature), such as in a single-chain variable domain fragment (scFv). In this configuration, the three hypervariable regions of each variable domain interact to form a single-chain variable domain. H -V L The antigen binding site is defined on the surface of the dimer. Collectively, these six hypervariable regions or a subset thereof confer antigen binding specificity to the antibody.
[0062] A "single-chain Fv" or "scFv" antibody comprises the V H and V L domains, wherein these domains are present in a single polypeptide chain. Typically, the Fv polypeptide is further H and V L A polypeptide linker is included between the domains, which enables the scFv to form the desired structure for antigen binding. For a review of scFv, see Pluckthun, 1994, In: The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore eds. Springer-Verlag, New York, pp. 269-315.
[0063] A "single-chain Fab" or "scFab" antibody comprises the V H , C H 1. V L and C L domains, wherein these domains are present in a single polypeptide chain. H and CL or V L and C H A polypeptide linker is included between the 1 domains, which enables the scFab to form the desired structure for antigen binding (Koerber et al. (2015) J Mol Biol. 427:576-86).
[0064] The term "diabodies" refers to small antibody fragments with two antigen-binding sites, wherein the fragments are contained on the same polypeptide chain (V H and V L ) is connected to the light chain variable domain (V L )'s heavy chain variable domain (V H ). By using a linker that is too short to allow pairing between two variable domains on the same chain, the variable domains are forced to pair with the complementary domains of another chain, creating two antigen-binding sites.
[0065] The expression "linear antibody" refers to antibodies as described in Zapata et al. (1995) Protein Eng. 8: 1057-1062. Briefly, these antibodies contain a pair of tandem Fd segments (V H -C H 1-V H -C H 1), which together with the complementary light chain polypeptide forms a pair of antigen binding regions. Linear antibodies can be bispecific or monospecific.
[0066] Antibody fragments can be obtained using conventional recombinant or protein engineering techniques, and these fragments can be screened for binding to FIX and its activated form, FX, or another function in the same manner as intact antibodies.
[0067] Antibody fragments of the invention can be prepared by truncation, for example by removing one or more amino acids from the N-terminus and / or C-terminus of the polypeptide. Fragments can also be generated by one or more internal deletions.
[0068] The antibody of the present invention may be or may comprise a fragment of an antibody or a variant of any of the antibodies disclosed herein. The antibody of the present invention may be or may comprise an antigen binding portion of one of these antibodies or a variant thereof. For example, the antibody of the present invention may be a Fab fragment of one of these antibodies or a variant thereof, or it may be a single-chain antibody derived from one of these antibodies or a variant thereof. Moreover, the antibody of the present invention may be a combination of a full-length antibody and a fragment thereof.
[0069] The term "one-arm" as used herein refers to a specific type of monovalent antibody composed of an antibody heavy chain, a truncated heavy chain lacking the Fab region, and a single light chain.
[0070] As used herein, the term "monospecific" antibody refers to an antibody (including but not limited to bivalent antibodies) that is capable of binding to one specific epitope.
[0071] The term "bispecific" antibody as used herein refers to an antibody that is capable of binding to two different antigens or two different epitopes on the same antigen.
[0072] The term "trispecific" antibody as used herein refers to an antibody capable of binding to three different antigens, or three different epitopes on the same antigen, or three different epitopes present on two different antigens.
[0073] As used herein, the term "multispecific" antibody refers to an antibody that is capable of binding to two or more different antigens or two or more different epitopes on the same antigen. Therefore, multispecific antibodies include bispecific and trispecific antibodies.
[0074] Bispecific antibodies in full-length IgG format can be generated by fusion of two separate hybridomas to form a hybrid tetravalent tumor that produces an antibody mixture including a portion of a bispecific heterodimeric antibody (Chelius D. et al.; MAbs. 2010 May-June; 2(3): 309–319). Alternatively, bispecific heterodimeric antibodies can be produced using recombinant technology. Heterodimerization can also be achieved by modifying the dimerization interface of the Fc region to promote heterodimerization. One example is the so-called knob-in-hole mutation, in which a sterically bulky side chain (knob) is introduced into an Fc that is matched by a sterically smaller side chain (hole) on the relative Fc, thereby generating steric complementarity that promotes heterodimerization. Other methods for engineering heterodimeric Fc interfaces are electrostatic complementation, fusion with non-IgG heterodimerization domains, or utilizing the natural Fab-arm exchange phenomenon of human IgG4 to control heterodimerization. Examples of heterodimerized bispecific antibodies are well described in the literature, for example (Klein C et al.; MAbs. 2012 Nov-Dec; 4 (6): 653–663). Special attention must be paid to the light chain in the heterodimeric antibody. The correct pairing of LC and HC can be achieved by using a common light chain. Again, the engineering of the LC / HC interface can be used to promote heterodimerization or light chain cross-engineering, such as CrossMabs. Under mild reducing conditions, reassembly of antibodies from two separate IgG containing appropriate mutations in vitro can also be used to produce bispecific antibodies (e.g., Labrijn et al., PNAS, 110, 5145-5150 (2013)). Natural Fab-arm exchange methods have also been reported to ensure correct light chain pairing. Molecules based on multispecific antibodies can also be recombinantly expressed as fusion proteins that combine the natural modules of IgG to form multispecific and multivalent antibody derivatives as described in the literature. Examples of fusion antibodies are DVD-Ig, IgG-scFV, double antibodies, DARTs, etc. Specific detection or purification tags, half-life extension moieties or other components can be incorporated into the fusion protein. Additional non-IgG patterns can also be incorporated into the fusion protein. Bispecific full-length antibodies based on Fc heterodimerization are often referred to as asymmetric IgGs, regardless of the LC pairing method.
[0075] Generally, as reviewed by Brinkmann et al. (Brinkmann et al. The making of bispecific antibodies. Mabs 9, 182-212 (2017)), bispecific antibodies can be produced in a variety of molecular formats.
[0076] Molecules based on multispecific antibodies can also be produced by chemically conjugating or coupling a separate full-length IgG or a fragment of coupled IgG to form a multispecific and multivalent antibody derivative as described in the literature. Examples are chemically coupled Fab fragments, IgG-dimers, etc. Specific detection or purification tags, half-life extension molecules or other components can be incorporated into the conjugated protein. Additional non-IgG polypeptides can also be incorporated into the fusion protein. Multispecific molecules can also be produced by combining recombinant and chemical methods, including those methods described above.
[0077] In one aspect, the antibody of the present invention is a chimeric antibody, a human antibody or a humanized antibody. Such an antibody can be produced by using, for example, a suitable antibody display or immune platform or other suitable platforms or methods known in the art. As used herein, the term "human antibody" is intended to include antibodies with variable domains, in which at least a portion of the framework region and / or at least a portion of the CDR region are derived from human germline immunoglobulin sequences. For example, human antibodies may have variable domains in which the framework region and the CDR region are both derived from human germline immunoglobulin sequences. In addition, if the antibody contains a constant region, the constant region or a portion thereof is also derived from human germline immunoglobulin sequences. The human antibody of the present invention may include amino acid residues that are not encoded by human germline immunoglobulin sequences (for example, mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutations in vivo).
[0078] Such human antibodies can be human monoclonal antibodies. Such human monoclonal antibodies can be produced by hybridomas comprising B cells fused with immortalized cells, the B cells being obtained from transgenic non-human animals, such as transgenic mice, having a genome comprising a full repertoire of human immunoglobulin heavy and light chain gene segments.
[0079] Human antibodies can be isolated from sequence libraries created based on selections of human germline sequences and further diversified with natural and synthetic sequence diversity.
[0080] Human antibodies can be prepared by in vitro immunization of human lymphocytes and subsequent transformation of the lymphocytes with Epstein-Barr virus.
[0081] Human antibodies can be produced by recombinant methods known in the art.
[0082] The term "human antibody derivative" refers to any modified form of a human antibody, such as a conjugate of an antibody with another substance or antibody.
[0083] As used herein, the term "humanized antibody" refers to a human / non-human antibody containing a sequence (CDR region or part thereof) derived from a non-human immunoglobulin. Therefore, a humanized antibody is such a human immunoglobulin (acceptor antibody) in which at least the residues from the hypervariable region of the acceptor are replaced by residues from the hypervariable region of an antibody (donor antibody) of a non-human species such as a mouse, rat, rabbit or non-human primate, which has the desired specificity, affinity, sequence composition and functionality. In some cases, the framework (FR) residues of a human immunoglobulin are replaced by corresponding non-human residues. An example of such modification is the introduction of one or more so-called back mutations, which are generally amino acid residues derived from donor antibodies. The humanization of antibodies can be carried out using recombinant techniques known to those skilled in the art (see, for example, Antibody Engineering, Methods in Molecular Biology, vol. 248, edited by Benny K. Lo). The human acceptor framework suitable for both the light chain and heavy chain variable domains can be identified by, for example, sequence or structural homology. Alternatively, for example, a fixed acceptor framework can be used based on the understanding of structure, biophysics and biochemical properties. The acceptor framework can be germline derived or derived from a mature antibody sequence. The CDR region from the donor antibody can be transferred by CDR transplantation. The humanized antibodies of CDR transplantation can be further optimized in terms of, for example, affinity, functionality and biophysical properties by determining the key framework positions, and the amino acid residues from the donor antibody are reintroduced (back mutation) at the key framework positions to have a favorable effect on the properties of the humanized antibodies. Except for the back mutation derived from the donor antibody, humanized antibodies can also be engineered by introducing germline residues, eliminating immunogenic epitopes, site-directed mutagenesis, affinity maturation, etc. in CDR or framework regions.
[0084] In addition, humanized antibodies may include residues not found in the recipient antibody or the donor antibody. These modifications are made to further improve antibody performance. Typically, a humanized antibody will include at least one, generally two, variable domains, wherein all or substantially all of the CDR regions correspond to the CDR regions of a non-human immunoglobulin, and wherein all or substantially all of the FR residues are FR residues of a human immunoglobulin sequence. A humanized antibody may also optionally include at least a portion of an immunoglobulin constant region (Fc), generally a corresponding portion of a human immunoglobulin.
[0085] The term "humanized antibody derivative" refers to any modified form of a humanized antibody, such as a conjugate of an antibody with a chemical agent or a conjugate of an antibody with another antibody.
[0086] As used herein, the term "chimeric antibody" refers to an antibody comprising portions of antibodies derived from two or more species. For example, the genes encoding such antibodies include genes encoding variable domains derived from two different species and genes encoding constant domains derived from two different species. For example, a gene encoding a mouse monoclonal antibody variable domain can be linked to a gene encoding a human antibody constant domain.
[0087] The fragment crystallizable region ("Fc region" / "Fc domain") of an antibody is the region containing the hinge and constant C H 2 and C H The Fc domain is an antibody C-terminal region of a 3-domain. The Fc domain can interact with cell surface receptors known as Fc receptors and some proteins of the complement system. The Fc region enables antibodies to interact with the immune system. In one aspect of the invention, antibodies can be engineered to include modifications in the Fc region, generally used to change one or more of its functional properties, such as serum half-life, complement fixation, Fc receptor binding, protein stability and / or antigen-dependent cellular toxicity, or the lack of these properties, etc. In addition, the antibodies of the present invention can be chemically modified (e.g., one or more chemical moieties can be attached to the antibody) or modified to change its glycosylation, thereby again changing one or more functional properties of the antibody. IgG1 antibodies can carry a modified Fc domain that includes one or more and possibly all of the following mutations, which will result in reduced affinity for certain Fc-γ receptors (L234A, L235E and G237A) and reduced complement fixation mediated by C1q (A330S and P331S) (residues are numbered according to the EU index). Alternatively, other amino acid substitutions and combinations thereof known in the art and in combination with the modifications described above may be used to result in altered (decreased or increased) Fc-gamma receptor binding.
[0088] The isotype of the antibodies of the present invention can be IgG, such as IgG1, such as IgG2, such as IgG4. If necessary, the class of the antibody can be "converted" by known techniques. For example, an antibody initially produced as an IgM molecule can be converted to an IgG antibody. Class switching technology can also be used to convert one IgG subclass into another subclass, for example: from IgG1 to IgG2 or IgG4; from IgG2 to IgG1 or IgG4; or from IgG4 to IgG1 or IgG2. Antibody engineering can also be performed to generate constant region chimeric molecules by combining regions from different IgG subclasses.
[0089] In one embodiment, the hinge region of the antibody is modified such that the number of cysteine residues in the hinge region is altered, e.g., increased or decreased. This approach is further described in, e.g., U.S. Pat. No. 5,677,425 to Bodmer et al.
[0090] The constant region can be modified to stabilize the antibody, for example, to reduce the risk of bivalent antibodies separating into half antibodies. For example, in the IgG4 constant region, residue S228 (according to the EU numbering index, S241 according to Kabat) can be mutated to a proline (P) residue to stabilize the inter-heavy chain disulfide bond formation at the hinge (see, e.g., Angal et al. Mol Immunol. 1993; 30: 105-8).
[0091] Antibodies or fragments thereof can be defined according to their complementary determining regions (CDRs). The term "complementarity determining region" or "hypervariable region" when used herein refers to the region of the antibody in which the amino acid residues involved in antigen binding are located. Hypervariable regions or CDRs can be identified as regions with the highest variability in the amino acid alignment of the antibody variable domains. Databases such as the Kabat database can be used for CDR identification, for example, CDRs are defined as amino acid residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) of the light chain variable domain and 31-35 (H1), 50-65 (H2) and 95-102 (H3) of the heavy chain variable domain; (Kabat et al. 1991; Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242). Alternatively, the CDRs may be defined as those residues from a "hypervariable loop" (residues 26-33 (L1), 50-52 (L2), and 91-96 (L3) in the light chain variable domain and 26-32 (H1), 53-55 (H2), and 96-101 (H3) in the heavy chain variable domain; Chothia and Lesk, J. Mol. Biol. 1987; 196: 901-917). Typically, the numbering of amino acid residues in this region is by the method described by Kabat et al. (supra). Phrases such as "Kabat position", "Kabat residue", and "according to Kabat" herein refer to this numbering system for a heavy chain variable domain or a light chain variable domain. By using the Kabat numbering system, the actual linear amino acid sequence of a peptide may contain fewer or additional amino acids, corresponding to a shortening of the framework (FR) or CDR of the variable domain or an insertion therein. For example, the heavy chain variable domain may comprise an amino acid insertion after residue 52 of CDRH2 (residues 52a, 52b, and 52c according to Kabat) and a residue inserted after heavy chain FR residue 82 (e.g., residues 82a, 82b, and 82c, etc. according to Kabat). The Kabat numbering of residues for a given antibody can be determined by aligning regions of homology of the antibody sequence with "standard" Kabat numbered sequences.
[0092] The term "framework region" or "FR" residues refers to those V residues that are not within the CDRs as defined herein. H or V L Amino acid residues.
[0093] The antibodies of the invention may comprise CDR regions from one or more specific antibodies disclosed herein.
[0094] The term "procoagulant antibody" refers to an antibody that enhances blood coagulation, for example by accelerating the blood coagulation process and / or increasing the enzymatic activity of one or more coagulation factors.
[0095] The term "procoagulant activity" refers to the ability of a compound, such as an antibody, to enhance blood coagulation, for example by accelerating the blood coagulation process and / or increasing the enzymatic activity of one or more coagulation factors.
[0096] The term "antigen" (Ag) refers to a molecular entity used to immunize an immunocompetent vertebrate to produce an antibody (Ab) that recognizes the Ag. In this article, Ag has a broader meaning and is generally intended to include a target molecule specifically recognized by Ab, thus including a molecular fragment or mimic used in an immune process or other process such as phage display for producing Ab.
[0097] As used herein, the term "epitope" is defined in the context of molecular interactions between an "antigen binding polypeptide" such as an antibody (Ab) and its corresponding antigen (Ag). Typically, an "epitope" refers to a region or area on the Ag that binds to the Ab, i.e., a region or area in physical contact with the Ab. Physical contact can be achieved using various criteria for atoms in the Ab and Ag molecules (e.g., a distance cutoff of 1 to 200,000). like like like like like or solvent accessibility).
[0098] FIX / FIXa and FX / FXa may contain a number of different epitopes, which may include, but are not limited to (1) linear peptide epitopes; (2) conformational epitopes consisting of one or more non-contiguous amino acids that are close to each other in the mature FIX / FIXa or FX / FXa conformation; and (3) epitopes consisting in whole or in part of a molecular structure, such as a carbohydrate group, that is covalently attached to FIX / FIXa or FX / FXa.
[0099] A variety of experimental and computational epitope mapping methods can be used to describe and characterize the epitope of a given antibody (Ab) / antigen (Ag) pair at varying levels of detail. These experimental methods include mutagenesis, X-ray crystallography, nuclear magnetic resonance (NMR) spectroscopy, hydrogen deuterium exchange mass spectrometry (HDX-MS), and various competitive binding methods; methods known in the art. Because each method relies on a unique principle, the description of the epitope is closely related to the method by which the epitope is determined. Therefore, the epitope of a given Ab / Ag pair can be described differently depending on the epitope mapping method used.
[0100] In the context of an X-ray derived crystal structure defined by the spatial coordinates of a complex between an Ab, e.g., a Fab fragment, and its Ag, the term epitope is specifically defined herein as a FIX / FIXa or FX residue characterized by being located at a distance from a heavy atom in the Ab, unless otherwise indicated or contradicted by the context. There are heavy atoms (i.e. non-hydrogen atoms) within a distance of .
[0101] Epitopes described at the amino acid level, e.g., determined by X-ray structure, are said to be identical if they contain the same set of amino acid residues. Epitopes are said to overlap if they share at least one amino acid residue. Epitopes are said to be different (unique) if they share no amino acid residues.
[0102] The definition of the term "paratope" is derived from the above definition of "epitope" by reversing the perspective. Thus, the term "paratope" refers to the region or area on the Ab that binds to the Ag, i.e., the region or area that is in physical contact with the Ag.
[0103] In the context of an X-ray derived crystal structure defined by the spatial coordinates of a complex between an Ab, such as a Fab fragment, and its Ag, the term paratope is specifically defined herein as the Ab residues characterized by being within 100% of the heavy atoms in FIX / FIXa or FX, unless otherwise indicated or contradicted by the context. There are heavy atoms (i.e. non-hydrogen atoms) within a distance of .
[0104] The epitope and paratope of a given antibody (Ab) / antigen (Ag) pair can be identified by conventional methods. For example, the general position of an epitope can be determined by assessing the ability of an antibody to bind to different fragments or variants of FIX / FIXa or FX. The specific amino acids (epitopes) that contact the antibody in FIX / FIXa or FX and the specific amino acids (paratopes) that contact FIX / FIXa or FX in the antibody can also be determined using conventional methods. For example, an antibody and a target molecule can be combined, and the Ab:Ag complex can be crystallized. The crystal structure of the complex can be determined, and the specific site of interaction between the antibody and its target can be identified using it.
[0105] The epitope on the antigen may contain one or more hotspot residues, i.e., residues that are particularly important for interaction with a homologous antibody, and wherein the interaction mediated by the side chain of the hotspot residue significantly contributes to the binding energy for antibody / antigen interaction (Peng et al. (2014) PNAS 111, E2656-E2665). Hotspot residues can be identified by testing the binding of antigen (here FIX / FIXa and FX) variants in which a single epitope residue has been replaced with, for example, alanine to a homologous antibody. If the substitution of an epitope residue with alanine has a strong effect on the binding to the antibody, the epitope residue is considered to be a hotspot residue and is therefore particularly important for the binding of the antibody to the antigen.
[0106] Antibodies that bind to the same antigen can be characterized for their ability to bind simultaneously to their common antigen and can undergo "competitive binding" / "binning". In this context, the term "binning" refers to a method of grouping antibodies that bind to the same antigen. The "binning" of antibodies can be based on the competitive binding of two antibodies to their common antigen in an assay based on standard techniques.
[0107] The reference antibody is used to define the "bin" of antibodies. If the secondary antibody cannot bind to the antigen at the same time as the reference antibody, the secondary antibody is said to belong to the same "bin" as the reference antibody. In this case, the reference antibody and the secondary antibody compete for binding to the same part of the antigen and are therefore classified as "competing antibodies." If the secondary antibody can bind to the antigen at the same time as the reference antibody, the secondary antibody is said to belong to a different "bin." In this case, the reference antibody and the second antibody do not compete for binding to the same part of the antigen and are therefore classified as "non-competing antibodies."
[0108] Antibody "binning" does not provide direct information about the epitope.
[0109] Competing antibodies, i.e. antibodies belonging to the same "bin", may have the same epitope, overlapping epitopes, or even different epitopes. The latter is the case if the reference antibody that binds to its epitope on the antigen occupies the space required for the second antibody to contact its epitope on the antigen ("steric hindrance"). Non-competing antibodies typically have different epitopes. Thus, in some embodiments, an antibody of the invention will bind to the same epitope as at least one of the antibodies specifically disclosed herein.
[0110] Competition assays for determining whether an antibody competes for binding with an anti-FIX / FIXa or anti-X antibody disclosed herein are known in the art. Exemplary competition assays include immunoassays (e.g., ELISA assays, RIA assays), surface plasmon resonance analysis (e.g., using BIAcore TM Instrumentation), Biolayer Interferometry and flow cytometry.
[0111] Typically, competition assays involve the use of antigens, test FIX- or FIXa binding antibodies and reference antibodies that are combined with solid surfaces or expressed on cell surfaces. Reference antibodies are labeled, and test antibodies are not labeled. Competitive inhibition is measured by measuring the amount of labeled reference antibodies combined with solid surfaces or cells in the presence of test antibodies. Typically, test antibodies are present in excess (e.g., 1, 5, 10, 20, 100, 1000, 10000 or 100000 times). Antibodies identified as having competitiveness in competition assays (i.e., competitive antibodies) include antibodies that combine the same epitope or overlapping epitopes with reference antibodies, and antibodies that are close enough to adjacent epitopes to which the epitope combined with the reference antibodies is sterically hindered.
[0112] In an exemplary competition test, commercially available reagents are used to biotinylate a reference anti-FIX or anti-FIXa antibody. The biotinylated reference antibody is mixed with a serial dilution of a test antibody or an unlabeled reference antibody (from a competitive control) to obtain a mixture of a test antibody (or unlabeled reference antibody) and a labeled reference antibody at various molar ratios (e.g., 1, 5, 10, 20, 100, 1000, 10000 or 100000 times). The antibody mixture is added to an ELISA plate coated with a FIX or FIXa polypeptide. The plate is then washed and horseradish peroxidase (HRP)-streptavidin is added to the plate as a detection reagent. The amount of labeled reference antibody bound to the target antigen is detected after the addition of a chromogenic substrate known in the art (e.g., TMB (3,3',5,5'-tetramethylbenzidine) or ABTS (2,2"-azino-bis-(3-ethylbenzothiazoline-6-sulfonate)). Optical density readings (OD units) are measured using a spectrometer (e.g., M2 spectrometer (Molecular Devices)). The response (OD unit) corresponding to 0% inhibition was determined from the wells without any competing antibody. The response (OD unit) corresponding to 100% inhibition, i.e., the experimental background, was determined from the wells without any labeled reference antibody or test antibody. The percent inhibition of the labeled reference antibody of FIX or FIXa by the test antibody (or unlabeled reference antibody) at each concentration was calculated as follows: % inhibition = (1-(OD unit-100% inhibition) / (0% inhibition-100% inhibition))*100.
[0113] Those skilled in the art will appreciate that similar assays can be performed to determine whether two or more anti-FX / FXa antibodies share binding regions, bins, and / or compete for binding to an antigen. Those skilled in the art will also appreciate that competition assays can be performed using various detection systems known in the art. If an excess of one antibody (e.g., 1, 5, 10, 20, 100, 1000, 10000, or 100000-fold) inhibits the binding of the other antibody, such as by at least 50%, 75%, 90%, 95%, or 99% as measured in a competitive binding assay, then the test antibody competes with the reference antibody for binding to the antigen.
[0114] Unless otherwise stated, competition was determined using a competition ELISA assay as described above.
[0115] The term "binding affinity" is used herein as a measure of the strength of a non-covalent interaction between two molecules (eg, an antibody or fragment thereof and an antigen). The term "binding affinity" is used to describe a monovalent interaction.
[0116] By determining the equilibrium dissociation constant (K D ), the binding affinity between two molecules (e.g., an antibody or fragment thereof and an antigen) through a monovalent interaction can be quantified. K can be determined by measuring the kinetics of complex formation and dissociation, for example, by surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC). D The rate constants corresponding to the association and dissociation of the monovalent complex are called the association rate constants k and k, respectively. a (or k 结合 ) and the dissociation rate constant k d (or k 解离 ). Through equation K D =k d / k a , K D With k a and k d Associated.
[0117] According to the above definition, by comparing the K of individual antibody / antigen complexes D Values can be used to compare the binding affinities associated with different molecular interactions, such as comparing the binding affinities of different antibodies to a given antigen.
[0118] The value of the dissociation constant can be directly determined by well-known methods. Standard tests for evaluating the binding ability of ligands such as antibodies to targets are known in the art, and include, for example, ELISA, Western blotting, RIA, and flow cytometry analysis. The binding kinetics and binding affinity of antibodies can also be assessed by standard tests known in the art, such as SPR. However, preferably, isothermal titration calorimetry (ITC) can be used to measure the affinity of antibody / target interactions and to obtain the thermodynamic parameters of the interaction.
[0119] Competitive binding assays can be performed in which binding of an antibody to a target is compared to binding of another ligand for that target, such as another antibody.
[0120] The antibodies of the present invention may have a 1x10 -4 M or lower, 1x10 -5 M or lower, 1x10 -6 M or lower, 1x10 -7 M or lower, 1x10 -8 M or lower, or 1x10 -9 M or lower, or 1x10 -10 M or lower, 1x10 -11 M or lower, 1x10 -12 M or lower, 1x10 -13 M or lower, or 1x10 -14 M or lower K D .
[0121] The K of the antibody of the present invention D It may be less than 100 μM, such as less than 10 μM, such as less than 1 μM, such as less than 0.9 μM, such as less than 0.8 μM, such as less than 0.7 μM, such as less than 0.6 μM, such as less than 0.5 μM, such as less than 0.4 μM, such as less than 0.3 μM, such as less than 0.2 μM, such as less than 0.1 μM.
[0122] In one such embodiment, the antibody is a bispecific antibody comprising an anti-FX arm that is resistant to the K of FX. DLess than 100μM, such as less than 10μM, such as less than 1μM, such as less than 0.9μM, such as less than 0.8μM, such as less than 0.7μM, such as less than 0.6μM, such as less than 0.5μM, such as less than 0.4μM, such as less than 0.3μM, such as less than 0.2μM, such as less than 0.1μM, such as less than 0.09μM, such as less than 0.08μM, such as less than 0.07μM, such as less than 0.06μM, such as less than 0.05μM, such as less than 0.04μM, such as less than 0.03μM, such as less than 0.02μM, such as less than 0.01μM, such as less than 9nM, such as less than 8nM, such as less than 7nM, such as less than 6nM, such as less than 5nM, such as less than 4nM, such as less than 3nM, such as less than 2nM, such as less than 1nM, such as less than 0.5nM.
[0123] Antibodies and antibody fragments thereof as described herein can be combined with other antibodies and antibody fragments known in the art to produce bispecific, trispecific or multispecific antibody molecules. Previously, other FIX / IXa and FX / Xa binding domains have been used to produce compounds that simulate the function of FVIII cofactors, and these domains can potentially replace FIX / IXa and / or FX / Xa binding domains as described herein. It can be seen from this that the FIX / IXa and FX / Xa binding domains of the present invention have independent meanings as separate molecules and as "intermediates" of a part of a bispecific, trispecific or multispecific antibody comprising at least one FIX / IXa and / or FX / Xa binding domain.
[0124] The activity of procoagulant antibodies, including bispecific, trispecific and multispecific antibodies, can be determined by methods known in the art. Standard assays include whole blood-thrombin-generation test (TGT), measurement of clotting time by thromboelastography (TEG) and FXa generation test.
[0125] Identity
[0126] The term "identity" as known in the art refers to the relationship between the sequences of two or more polypeptides determined by comparing the sequences. In the art, "identity" also refers to the degree of sequence relatedness between polypeptides, as determined by the number of matches between residue strings of two or more amino acid residues. "Identity" measures the percentage of identical matches between the smaller sequences in two or more sequences, where gap comparisons (if any) are solved by a specific mathematical model or computer program (i.e., "algorithm"). The identity of related polypeptides can be easily calculated by known methods. Such methods include, but are not limited to, those described in Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, AM, and Griffin, HG, eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York, 1991; and Carillo et al. SIAM J. Applied Math. 1988; 48:1073.
[0127] Preferred methods for determining identity are designed to give the maximum match between the sequences tested. Methods for determining identity are described in publicly available computer programs. Preferred computer program methods for determining identity between two sequences include the GCG program package, including GAP (Devereux et al. Nucl. Acid. Res. 1984; 12: 387; Genetics Computer Group, University of Wisconsin, Madison, Wis.), BLASTP, BLASTN and FASTA (Altschul et al. J. Mol. Biol. 1990; 215: 403-410). The BLASTX program is publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul et al. NCB / NLM / NIHBethesda, Md. 20894; Altschul et al., supra). The well-known Smith Waterman algorithm can also be used to determine identity.
[0128] For example, using the computer algorithm GAP (Genetics Computer Group, University of Wisconsin, Madison, Wis.), the best match ("matched span", as determined by the algorithm) of the amino acids in each of the two polypeptides whose sequence identity percentage is to be determined is aligned. A gap opening penalty (which is calculated as 3 times the average diagonal; "average diagonal" is the average of the diagonals of the comparison matrix used; "diagonal" is the score or number assigned to each perfect amino acid match by a particular comparison matrix) and a gap extension penalty (which is typically 1 / 10 of the gap opening penalty) and a comparison matrix such as PAM 250 or BLOSUM 62 are used in conjunction with the algorithm. The algorithm also uses standard comparison matrices (for the PAM 250 comparison matrix, see Dayhoff et al. 1978; Atlas of Protein Sequence and Structure, vol. 5, supp. 3; for BLOSUM 62 comparison matrix, see Henikoff et al. PNAS 1992; 89: 10915-10919).
[0129] Preferred parameters for peptide sequence comparison include the following: Algorithm: Needleman et al. J. Mol. Biol. 1970; 48:443-453; Comparison matrix: BLOSUM 62 from Henikoff et al. PNAS 1992; 89:10915-10919; Gap penalty: 12, Gap length penalty: 4, Similarity threshold: 0.
[0130] The GAP program can use the parameters described above. The parameters described above are the default parameters for peptide comparisons using the GAP algorithm (and there is no penalty for terminal gaps).
[0131] The term "similarity" is a related concept, but is different from "identity", and refers to a sequence relationship comprising identical matching and conservative substitution matching. If two peptide sequences have, for example, 10 / 20 identical amino acids, and the rest are non-conservative substitutions, then the identity percentage and similarity percentage will all be 50%. If in the same example, there are also 5 positions with conservative substitutions, then the identity percentage is 25%, and the similarity percentage is 75% (fraction 15 / 20). Therefore, in the presence of conservative substitutions, the similarity degree between the two polypeptides will be higher than the identity percentage between the two polypeptides.
[0132] Pharmaceutical preparations
[0133] In another aspect, the invention provides compositions and formulations comprising compounds of the invention, such as antibodies described herein. For example, the invention provides pharmaceutical compositions comprising one or more antibodies of the invention formulated together with a pharmaceutically acceptable carrier.
[0134] Accordingly, an object of the present invention is to provide a pharmaceutical preparation comprising such an antibody present at a concentration of 0.25 mg / ml to 250 mg / ml, and wherein the preparation has a pH of 2.0 to 10.0. The preparation may further comprise one or more of a buffer system, a preservative, a tonicity agent, a chelating agent, a stabilizer or a surfactant and various combinations thereof. The use of preservatives, isotonic agents, chelating agents, stabilizers and surfactants in pharmaceutical compositions is well known to those skilled in the art. Reference may be made to Remington: The Science and Practice of Pharmacy, 19th edition, 1995.
[0135] In one embodiment, the pharmaceutical formulation is an aqueous formulation. Such formulations are generally solutions or suspensions, but may also include colloids, dispersions, emulsions, and multiphase materials. The term "aqueous formulation" is defined as a formulation comprising at least 50% w / w water. Similarly, the term "aqueous solution" is defined as a solution comprising at least 50% w / w water, and the term "aqueous suspension" is defined as a suspension comprising at least 50% w / w water.
[0136] In another embodiment, the pharmaceutical preparation is a freeze-dried preparation to which the physician or patient adds solvents and / or diluents prior to use.
[0137] In a further aspect, the pharmaceutical formulation comprises an aqueous solution of an antibody and a buffer, wherein the antibody is present at a concentration of 1 mg / ml or more, and wherein the formulation has a pH of about 2.0 to about 10.0.
[0138] Application
[0139] The compounds of the invention, such as antibodies, can be administered parenterally, such as intravenously, such as intramuscularly, such as subcutaneously. Alternatively, the antibodies of the invention can be administered non-parenterally, such as orally or topically. The antibodies of the invention can be administered prophylactically. The antibodies of the invention can be administered therapeutically (as needed).
[0140] dose
[0141] The dosage of the compound to be delivered can be about 0.01 mg to 500 mg of compound per day, per week, every two weeks or per month, preferably about 0.1 mg to 250 mg, more preferably about 0.5 mg to about 250 mg as load and maintenance dose, depending on the severity of the condition. Based on the properties of the compound, including its half-life or mean residence time in vivo and its biological activity, suitable dosage can also be adjusted for a particular compound. For example, in one embodiment, the compound to be delivered can be administered once a week, or once every other week in another embodiment, or once a month in another embodiment, and in any one of the embodiments, for example, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5 or 10 mg / kg body weight is administered.
[0142] Compositions containing compounds disclosed herein can be administered for preventive treatment and / or in some embodiments for therapeutic treatment. In therapeutic applications, the composition is administered to a subject who has already suffered from a disease such as any of the above-mentioned bleeding disorders in an amount sufficient to cure, alleviate or partially prevent the disease and its complications. An amount sufficient to achieve this purpose is defined as a "therapeutically effective amount". As will be appreciated by those skilled in the art, the amount effective for this purpose will depend on the severity of the disease or injury and the weight and general state of the subject.
[0143] Implementation
[0144] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue H256 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0145] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue H257 of FIX (SEQ ID NO: 1) or its activated form FIXa.
[0146] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue N258 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0147] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue K293 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0148] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue K301 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0149] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue D332 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0150] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue R333 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0151] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue A334 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0152] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue T335 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0153] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue L337 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0154] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue R338 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0155] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue S339 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0156] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue T340 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0157] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue K341 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0158] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue T343 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0159] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue N346 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0160] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue R403 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0161] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue Y404 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0162] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue N406 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0163] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue W407 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0164] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue E410 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0165] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residue K411 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0166] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residues L337, R338, S339, T340, K341 and T343 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0167] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residues K301, D332, R333, A334, T335, R338 and N346 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0168] In one embodiment, an antibody of the invention is capable of binding to an epitope comprising residues H256, H257, N258, K293, R403, Y404, N406, W407, E410 and K411 of FIX (SEQ ID NO: 1) or an activated form thereof (FIXa).
[0169] In one embodiment, the antibody of the invention is capable of binding to FIX (SEQ ID NO: 1) or an activated form thereof (FIXa), wherein the antibody competes with Fab7236 for binding to FIX.
[0170] In one embodiment, the antibody of the invention is capable of binding to FIX (SEQ ID NO: 1) or its activated form (FIXa), wherein the antibody competes with Fab7237 for binding to FIX.
[0171] In one embodiment, the antibody of the invention is capable of binding to FIX (SEQ ID NO: 1) or an activated form thereof (FIXa), wherein the antibody competes with Fab7238 for binding to FIX.
[0172] In one embodiment, an antibody of the invention binds to FIX (SEQ ID NO: 1) or an activated form thereof (FIXa), wherein the antibody belongs to the same "bin" as Fab7236.
[0173] In one embodiment, an antibody of the invention binds to FIX (SEQ ID NO: 1) or an activated form thereof (FIXa), wherein the antibody belongs to the same "bin" as Fab7237.
[0174] In one embodiment, an antibody of the invention binds to FIX (SEQ ID NO: 1) or an activated form thereof (FIXa), wherein the antibody belongs to the same "bin" as Fab7238.
[0175] In one embodiment, an antibody of the invention is capable of binding to FX (SEQ ID NO: 2) or its activated form FXa, wherein the antibody competes with an antibody comprising the CDRs of mAb 1-6723.
[0176] In one embodiment, an antibody of the invention is capable of binding to FX / FXa, wherein the antibody comprises the variable domains of mAb1-6723 according to SEQ ID NO:21 and SEQ ID NO:22.
[0177] In one embodiment, an antibody of the invention is capable of specifically binding to FX / FXa, wherein the antibody comprises the CDRs of mAb1-6723 according to SEQ ID NO:21 and SEQ ID NO:22.
[0178] In one embodiment, an antibody of the invention is capable of binding to FX / FXa, wherein said antibody belongs to the same "bin" as a Fab comprising the variable domains of mAb1-6723 according to SEQ ID NO:21 and SEQ ID NO:22.
[0179] In one embodiment, the antibody of the invention is capable of specifically binding to FX / FXa, wherein the antibody belongs to the same "bin" as mAb1-6723 comprising according to SEQ ID NO:21 and SEQ ID NO:22.
[0180] In one embodiment, the antibody of the invention is capable of specific binding to FX / FXa, wherein said antibody belongs to the same "bin" as the antibody or Fab comprising the antigen binding domain according to SEQ ID NO:21 and SEQ ID NO:22.
[0181] In one embodiment, an antibody of the invention is capable of binding to FX / FXa, wherein said antibody competes with an antibody comprising the CDRs of mAb 1-1371.
[0182] In one embodiment, an antibody of the invention is capable of binding to FX / FXa, wherein the antibody comprises the variable domains of mAb 1-1371 according to SEQ ID NO:65 and SEQ ID NO:66.
[0183] In one embodiment, an antibody of the invention is capable of binding to FX / FXa, wherein the antibody comprises the CDRs of mAb 1-1371 according to SEQ ID NO:65 and SEQ ID NO:66.
[0184] In one embodiment, an antibody of the invention is capable of binding FX / FXa, wherein said antibody belongs to the same "bin" as the Fab comprising the variable domains of mAbl-1371 according to SEQ ID NO:65 and SEQ ID NO:66, herein referred to as "bin A".
[0185] In one embodiment, an antibody of the invention is capable of binding to FX / FXa, wherein said antibody belongs to the same "bin" as mAb1-1371 according to SEQ ID NO:65 and SEQ ID NO:66.
[0186] In one embodiment, an antibody of the invention is capable of binding to FX / FXa, wherein said antibody belongs to the same "bin" as an antibody or Fab comprising an antigen binding domain according to SEQ ID NO: 65 and SEQ ID NO: 66.
[0187] In one embodiment, an antibody of the invention is capable of specific binding to FX / FXa, wherein the antibody competes with an antibody comprising the CDRs of mAb1-1376, mAb1-6705, mAb1-7388 or mAb1-7563. Such antibodies are referred to herein as belonging to box B.
[0188] In one embodiment, the antibody of the invention is capable of binding to FX / FXa, wherein the antibody comprises the variable domain of mAb1-1376, mAb1-6705, mAb1-7388 or mAb1-7563 represented by SEQ ID NOs: 67 and 68, SEQ ID NOs: 23 and 24, SEQ ID NOs: 39 and 40, and SEQ ID NOs: 59 and 60, respectively.
[0189] In one embodiment, the antibody of the invention is capable of binding to FX / FXa, wherein the antibody comprises the CDRs of mAb1-1376, mAb1-6705, mAb1-7388 or mAb1-7563 represented by SEQ ID NOs: 67 and 68, SEQ ID NOs: 23 and 24, SEQ ID NOs: 39 and 40, and SEQ ID NOs: 59 and 60, respectively.
[0190] In one embodiment, the antibody of the present invention is capable of binding to FX / FXa, wherein the antibody belongs to the same "bin" as a Fab comprising the variable domains of mAb1-1376, mAb1-6705, mAb1-7388 or mAb1-7563 represented by SEQ ID NOs: 67 and 68, SEQ ID NOs: 23 and 24, SEQ ID NOs: 39 and 40, and SEQ ID NOs: 59 and 60, respectively.
[0191] In one embodiment, the antibody of the invention is capable of binding to FX / FXa, wherein the antibody belongs to the same "bin" as mAb1-1376, mAb1-6705, mAb1-7388 or mAb1-7563 represented by SEQ ID NOs: 67 and 68, SEQ ID NOs: 23 and 24, SEQ ID NOs: 39 and 40, and SEQ ID NOs: 59 and 60, respectively.
[0192] In one embodiment, the antibody of the invention is capable of binding to FX / FXa, wherein the antibody belongs to the same "bin" as an antibody or Fab comprising an antigen binding domain according to SEQ ID NOs: 67 and 68, SEQ ID NOs: 23 and 24, SEQ ID NOs: 39 and 40 or SEQ ID NOs: 59 and 60.
[0193] In one embodiment, the antibody of the invention is capable of binding to FX / FXa, wherein the antibody comprises the CDRs or variable domains of an antibody selected from mAb 1-6723, 1-6716, 1-6721, 1-6730, 1-6731, 1-6737, 1-6754, 1-7378, 1-7413, 1-7424, 1-7466, 1-7481, 1-7483 and mAb 1-7591.
[0194] In one embodiment, the antibodies of the invention are capable of binding to FX / FXa, wherein the antibodies comprise the CDRs or variable domains of an antibody selected from mAb 1-6723, 1-6716, 1-6721, 1-6730, 1-6731, 1-6737, 1-6754, 1-7378, 1-7413, 1-7424, 1-7466, 1-7481, 1-7483, 1-7591, 1-7388, 1-7563, 1-7462 and mAb 1-7571.
[0195] In one embodiment, the antibody of the present invention is capable of binding to FX / FXa, wherein the antibody belongs to the same "bin" as a mAb selected from a mAb comprising a variable sequence or its CDR, which variable sequence or its CDR is selected from: SEQ ID NOs: 21 and 22, SEQ ID NOs: 25 and 26, SEQ ID NOs: 27 and 28, SEQ ID NOs: 29 and 30, SEQ ID NOs: 31 and 32, SEQ ID NOs: 33 and 34, SEQ ID NOs: 35 and 36, SEQ ID NOs: 37 and 38, SEQ ID NOs: 39 and 40, SEQ ID NOs: 41 and 42, SEQ ID NOs: 43 and 44, SEQ ID NOs: 45 and 46, SEQ ID NOs: 51 and 52, SEQ ID NOs: 53 and 54, SEQ ID NOs: 55 and 56, SEQ ID NOs: 57 and 58, SEQ ID NOs: 59 and 60, SEQ ID NOs: 61 and 62, and SEQ ID NOs: 63 and 64. Such an antibody "bin" is referred to herein as bin C, and is exemplified by a number of individual antibodies, such as mAb 1-6723, 1-6716, 1-6721, 1-6730, 1-6731, 1-6737, 1-6754, 1-7378, 1-7413, 1-7424, 1-7466, 1-7481, 1-7483, 1-7591, 1-7388, 1-7563, 1-7462, and mAb 1-7571.
[0196] In one embodiment, the antibody of the invention is capable of binding to FX / FXa, wherein the antibody competes for binding to FX, FX proenzyme or FXa with a reference antibody selected from the group consisting of an mAb comprising a variable sequence or its CDRs selected from the group consisting of: SEQ ID NOs: 21 and 22, SEQ ID NOs: 25 and 26, SEQ ID NOs: 27 and 28, SEQ ID NOs: 29 and 30, SEQ ID NOs: 31 and 32, SEQ ID NOs: 33 and 34, SEQ ID NOs: 35 and 36, SEQ ID NOs: 37 and 38, SEQ ID NOs: 41 and 42, SEQ ID NOs: 43 and 44, SEQ ID NOs: 53 and 54, SEQ ID NOs: 55 and 56, SEQ ID NOs: 57 and 58, and SEQ ID NOs: 63 and 64.
[0197] In one embodiment, an antibody or antigen-binding fragment thereof of the invention competes for binding to FX / FXa with an antigen-binding fragment comprising the CDRs of SEQ ID NOs: 21 and 22, SEQ ID NOs: 25 and 26, SEQ ID NOs: 27 and 28, SEQ ID NOs: 29 and 30, SEQ ID NOs: 31 and 32, SEQ ID NOs: 33 and 34, SEQ ID NOs: 35 and 36, SEQ ID NOs: 37 and 38, SEQ ID NOs: 41 and 42, SEQ ID NOs: 43 and 44, SEQ ID NOs: 53 and 54, SEQ ID NOs: 55 and 56, SEQ ID NOs: 57 and 58, or SEQ ID NOs: 63 and 64.
[0198] In one embodiment, an antibody of the invention is capable of binding to FX / FXa, wherein the antibody competes with an antibody comprising the CDRs of mAb 1-7447, 1-7441, 1-7571 or 1-7462. These are referred to herein as antibodies of box D.
[0199] In one embodiment, the antibody of the invention is capable of binding to FX / FXa, wherein the antibody comprises the variable domain of mAb 1-7447, 1-7441, 1-7571 or 1-7462 according to SEQ ID NOs: 47 and 48, SEQ ID NOs: 45 and 46, SEQ ID NOs: 51 and 53 or SEQ ID NOs: 61 and 62, respectively.
[0200] In one embodiment, an antibody of the invention is capable of binding to FX / FXa, wherein the antibody comprises the variable domain of mAb 1-7447 or 1-7441 according to SEQ ID NOs: 47 and 48, SEQ ID NOs: 45 and 46, respectively.
[0201] In one embodiment, an antibody of the invention is capable of binding FX / FXa, wherein the antibody comprises the CDRs of mAb 1-7447, 1-7441, 1-7571 or 1-7462 according to SEQ ID NOs: 47 and 48, SEQ ID NOs: 45 and 46, SEQ ID NOs: 51 and 53, or SEQ ID NOs: 61 and 62, respectively.
[0202] In one embodiment, the antibody of the invention is capable of binding to FX / FXa according to SEQ ID NO: 2, wherein the antibody belongs to the same "bin" as a Fab comprising the variable domains of mAb1-7447, 1-7441, 1-7571 or mAb1-7462 according to SEQ ID NOs: 47 and 48, SEQ ID NOs: 45 and 46, SEQ ID NOs: 51 and 53 or SEQ ID NOs: 61 and 62, respectively.
[0203] In one embodiment, the antibody of the invention is capable of binding to FX / FXa, wherein the antibody belongs to the same "bin" as mAb1-7447, 1-7441, 1-7571 or mAb1-7462 according to SEQ ID NOs: 47 and 48, SEQ ID NOs: 45 and 46, SEQ ID NOs: 51 and 53 or SEQ ID NOs: 61 and 62, respectively.
[0204] In one embodiment, the antibody of the invention is capable of binding to FX / FXa, wherein the antibody belongs to the same "bin" as an antibody or Fab comprising an antigen binding domain according to SEQ ID NOs: 47 and 48, SEQ ID NOs: 45 and 46, SEQ ID NOs: 51 and 53 or SEQ ID NOs: 61 and 62.
[0205] In one embodiment, the antibody of the invention is an antibody according to any one of the preceding embodiments, wherein said antibody specifically binds to FX zymogen.
[0206] In such embodiments, the antibody specifically binds to FX zymogen according to amino acid residues 1-139, 143-448 of SEQ ID NO:2.
[0207] In one embodiment, the antibody of the invention is an antibody according to any one of the preceding embodiments, wherein said antibody binds FX.
[0208] In one embodiment, the antibody of the invention is an antibody according to any one of the preceding embodiments, wherein said antibody binds FXa.
[0209] In one such embodiment, the antibody specifically binds FXa according to amino acid residues 1-139, 195-448 of SEQ ID NO:2.
[0210] In one embodiment, the antibody is a monospecific antibody. In one embodiment, the antibody is a multispecific antibody. In one embodiment, the antibody is a bispecific antibody. In one such embodiment, the bispecific antibody can be combined with FIX or its activated form (FIXa) and FX / FXa. In one such embodiment, the bispecific antibody can specifically bind to FIX / FIXa and FX / FXa.
[0211] In one embodiment, the antibody is a bispecific antibody capable of binding to FIX / FIXa and FX / FXa, wherein the FIX / FIXa binding domain is derived from an antibody of box 1 and the FX / FXa binding domain is derived from an antibody of box A.
[0212] In one embodiment, the antibody is a bispecific antibody that binds FIX / FIXa and FX / FXa, wherein the FIX / FIXa binding domain is derived from an antibody of box 2 and the FX / FXa binding domain is derived from an antibody of box A.
[0213] In one embodiment, the antibody is a bispecific antibody that binds FIX / FIXa and FX / FXa, wherein the FIX / FIXa binding domain is derived from an antibody of box 2 and the FX / FXa binding domain is derived from an antibody of box B.
[0214] In one embodiment, the antibody is a bispecific antibody that binds FIX / FIXa and FX / FXa, wherein the FIX / FIXa binding domain is derived from an antibody of box 2 and the FX / FXa binding domain is derived from an antibody of box B.
[0215] In one embodiment, the antibody is a bispecific antibody that binds FIX / FIXa and FX / FXa, wherein the FIX / FIXa binding domain is derived from an antibody of box 1 and the FX / FXa binding domain is derived from an antibody of box C or D.
[0216] In one embodiment, the antibody is a bispecific antibody that binds FIX / FIXa and FX / FXa, wherein the binding domains are derived from mAb1-1371 / mAb1-1307, mAb1-6705 / mAb1-1307, mAb1-1371 / mAb0-1886, mAb1-7441 / mAb0-1886, mAb1-7447 / mAb0-1886, mAb1-7481 / mAb0-1886, mAb1-1371 / mAb0-1998, mAb1-6716 / mAb0-1998, mAb1-6723 / mAb0-1998, mAb1-6730 / mAb0-1998, mAb1-6731 / mAb0-19 98. mAb1-6737 / mAb0-1998, mAb1-6754 / mAb0-1998, mAb1-7378 / mAb0-1998, mAb1-7441 / mAb0-1998, mAb1-7 447 / mAb0-1998, mAb1-7481 / mAb0-1998, mAb1-1371 / mAb1-4707, mAb1-6705 / mAb1-4707, mAb1-1371 / mAb1 -4071, mAb1-7441 / mAb1-5788, mAb1-7447 / mAb1-5788, mAb1-7481 / mAb1-5788, mAb1-1371 / mAb1-4857, mAb or
[0217] mAb pair consisting of mAb1-7481 / mAb1-4857.
[0218] In one embodiment, the bispecific antibody of the invention comprises an antibody arm that binds to FX and an antibody arm that binds to FIX / FIXa. In one such embodiment, the antibody arm that binds to FX binds to an epitope that comprises one or more residues in the FX activation peptide, and the antibody arm that binds to FIX / FIXa binds to an epitope that comprises one or more residues in the FIX protease domain.
[0219] In one embodiment, the antibody of the invention is a multispecific antibody, such as a bispecific antibody or a trispecific antibody.
[0220] In one embodiment, the antibody of the invention is in the form of an IgG, such as a full length IgG4.
[0221] In one embodiment, the antibody of the invention is a chemical conjugate of two antibody fragments, such as a conjugate of two Fab fragments or scFv fragments, or a combination thereof.
[0222] In one embodiment, the antibodies of the invention are human antibodies or humanized antibodies.
[0223] In one embodiment, the antibodies disclosed herein are intermediates for the preparation of bispecific antibodies.
[0224] In one embodiment, the invention includes antibodies that compete with the antibodies disclosed herein for binding to FIX / FIXa.
[0225] The antibodies of the present invention can be used to treat subjects with coagulopathy, particularly hemophilia A. Therefore, the present invention also relates to the use of monoclonal antibodies capable of binding to the protease domain of FIX / FIXa in treating subjects in need; and the use of said antibodies in the preparation of a medicament for treating subjects in need. In addition, the present invention includes methods of treating subjects in need with monoclonal antibodies capable of binding to the protease domain of FIX / FIXa.
[0226] In one embodiment, an antibody of the invention is capable of binding FIXa with a higher affinity than it binds FIX.
[0227] In one embodiment, the antibodies of the invention are capable of increasing the enzymatic activity of FIXa towards FX.
[0228] In one such embodiment, the antibodies of the invention are capable of increasing the enzymatic activity of FIXa towards FX as measured in a FXa generation assay using a monovalent one-armed antibody as described herein.
[0229] In one embodiment, the antibodies of the invention are capable of increasing the enzymatic activity of FIXa towards FX as measured in a FXa generation assay using a bivalent antibody as described herein.
[0230] In one embodiment, the antibody of the invention is not the anti-FIX antibody CLB-FIX 13 as described in Rohlena et al. (2003) J. Biol. Chem. 278 (11): 9394-9401. In one embodiment, the antibody of the invention is not the anti-FIX antibody HIX-1 (IgG1 mouse) (Merck KGaA, Sigma Aldrich). In one embodiment, the antibody of the invention is not the anti-FIX antibody AHIX-5041 (IgG1) (Haematologic Technologies, Inc.).
[0231] In one embodiment, the antibodies of the invention have reduced immunogenicity compared to procoagulant antibodies in the art.
[0232] In one embodiment, the bispecific antibody or antigen-binding fragment thereof comprises a first antigen-binding site that recognizes FIX (SEQ ID NO: 1) or an activated form thereof (FIXa) and a second antigen-binding site that recognizes FX (SEQ ID NO: 2) or an activated form thereof (FXa), wherein
[0233] a) The first antigen binding site comprises the following CDR sequences:
[0234] V H -CDR1: DYAMH
[0235] V H -CDR2:GISWRGDIIGYVDSVKG
[0236] V H -CDR3:SYGSGSFYNAFDS
[0237] V L -CDR1:RASQSISSWLA
[0238] V L -CDR2:KASRLDR
[0239] V L -CDR3:LEYSSYIRT
[0240] and
[0241] b) The second antigen binding site comprises the following CDR sequences:
[0242] V H -CDR1:TSWIV
[0243] V H -CDR2:MIDPSDSFTSYSPSFQG
[0244] V H -CDR3:LHYYHSEEFDV
[0245] V L -CDR1:RASQSVSSSYLA
[0246] V L -CDR2: GASSRAR
[0247] V L -CDR3:QQFGSSRLFT
[0248] In one embodiment, the bispecific antibody or antigen-binding fragment thereof comprises a first antigen-binding site that recognizes FIX (SEQ ID NO: 1) or an activated form thereof (FIXa) and a second antigen-binding site that recognizes FX (SEQ ID NO: 2) or an activated form thereof (FXa), wherein
[0249] a) The first antigen binding site comprises the following CDR sequences:
[0250] V H -CDR1: DYAMH
[0251] V H -CDR2:GISWRGDIIGYVDSVKG
[0252] V H -CDR3:SYGSGSFYNAFDS
[0253] V L -CDR1:RASQSISSWLA
[0254] V L -CDR2:KASRLDR
[0255] V L -CDR3:LEYSSYIRT
[0256] and
[0257] b) The second antigen binding site comprises the following CDR sequences:
[0258] V H -CDR1:TSWIV
[0259] V H -CDR2:MIDPSDSFTSYSPSFQG
[0260] V H -CDR3:LHYYHSEEFDV
[0261] VL -CDR1:RASQSVSSSYLA
[0262] V L -CDR2: GASSRTR
[0263] V L -CDR3:QQFGSSRLFT
[0264] The present invention is further described by the following embodiments:
[0265] 1. An antibody or antigen-binding fragment thereof capable of binding to Factor IX (FIX) or an activated form thereof (FIXa) according to SEQ ID NO: 1.
[0266] 2. The antibody or antigen-binding fragment thereof according to embodiment 1, wherein the antibody or antigen-binding fragment thereof is part of "Box 1".
[0267] 3. The antibody or antigen-binding fragment thereof according to embodiment 1, wherein the antibody or antigen-binding fragment thereof competes with a reference antibody, wherein the reference antibody comprises
[0268] a. a heavy chain variable domain represented by SEQ ID NO: 15 and a light chain variable domain represented by SEQ ID NO: 16, or
[0269] b. The heavy chain variable domain represented by SEQ ID NO: 19 and the light chain variable domain represented by SEQ ID NO: 20.
[0270] 4. The antibody according to the preceding embodiment, wherein the reference antibody is a Fab.
[0271] 5. The antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0272] a. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 15 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 16,
[0273] b. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 19 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 20,
[0274] c. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 69 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 70,
[0275] d. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 71 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 72,
[0276] e. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 73 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 74,
[0277] f. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 83 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 84,
[0278] g. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 81 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 82,
[0279] h. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 75 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 76,
[0280] i. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 77 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 78, or
[0281] j. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 177 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 178.
[0282] 6. The antibody or antigen-binding fragment thereof according to embodiment 5, wherein the heavy chain variable domain is at least 92%, 94%, 96% or 98% identical to the SEQ ID as shown.
[0283] 7. The antibody or antigen-binding fragment thereof according to embodiment 5, wherein the light chain variable domain is at least 92%, 94%, 96% or 98% identical to the SEQ ID as shown.
[0284] 8. The antibody or antigen-binding fragment thereof according to embodiments 6 and 7, wherein the heavy chain variable domain and the light chain variable domain are both at least 92%, 94%, 96% or 98% identical to the SEQ ID as shown.
[0285] 9. The antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0286] a.
[0287] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 15, and
[0288] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 16,
[0289] b.
[0290] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 19, and
[0291] ii. Three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 20
[0292] c.
[0293] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 69, and
[0294] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 70, d.
[0295] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 71, and
[0296] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 72, e.
[0297] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 73, and
[0298] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 74, f.
[0299] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 83, and
[0300] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 84, g.
[0301] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 81, and
[0302] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 82, h.
[0303] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 75, and
[0304] ii. three light chain variable domain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 76, or
[0305] i.
[0306] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 77, and
[0307] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 78, or
[0308] j.
[0309] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 177, and
[0310] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 178.
[0311] 10. The antibody or antigen-binding fragment thereof according to embodiment 9, wherein the three heavy chain CDR sequences have at most 9, such as 8, such as 7 or such as 6 amino acid changes compared to the CDRs of the SEQ IDs shown.
[0312] 11. The antibody or antigen-binding fragment thereof according to embodiment 9, wherein the three heavy chain CDR sequences have at most 5, such as 4, such as 3, such as 2 or at most 1 amino acid changes compared to the CDRs of the SEQ IDs shown.
[0313] 12. The antibody or antigen-binding fragment thereof according to embodiment 9, wherein the three light chain CDR sequences have at most 9, such as 8, such as 7 or such as 6 amino acid changes compared to the CDRs of the SEQ IDs shown.
[0314] 13. An antibody or antigen-binding fragment thereof according to embodiment 9, wherein the three light chain CDR sequences have at most 5, such as 4, such as 3, such as 2 or at most 1 amino acid changes compared to the CDRs of the SEQ IDs shown.
[0315] 14. The antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0316] a. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 15 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 16, or
[0317] b. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 19 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 20, or
[0318] c. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 3 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 4, or
[0319] d. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 109 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 110, or
[0320] e. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 153 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 154, or
[0321] f. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 171 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 172, or
[0322] g. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 177 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 178, or
[0323] h. The CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 187 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 188.
[0324] 15. The antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0325] a. a heavy chain variable domain represented by SEQ ID NO: 15 and a light chain variable domain represented by SEQ ID NO: 16, or
[0326] b. a heavy chain variable domain represented by SEQ ID NO: 19 and a light chain variable domain represented by SEQ ID NO: 20, or
[0327] c. a heavy chain variable domain represented by SEQ ID NO: 3 and a light chain variable domain represented by SEQ ID NO: 4, or
[0328] d. a heavy chain variable domain represented by SEQ ID NO: 109 and a light chain variable domain represented by SEQ ID NO: 110, or
[0329] e. a heavy chain variable domain represented by SEQ ID NO: 153 and a light chain variable domain represented by SEQ ID NO: 154, or
[0330] f. a heavy chain variable domain represented by SEQ ID NO: 171 and a light chain variable domain represented by SEQ ID NO: 172, or
[0331] g. a heavy chain variable domain represented by SEQ ID NO: 177 and a light chain variable domain represented by SEQ ID NO: 178, or
[0332] h. the heavy chain variable domain represented by SEQ ID NO: 187 and the light chain variable domain represented by SEQ ID NO: 188.
[0333] 16. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising one or more of amino acid residues L337, R338, S339, T340, K341 and T343 of SEQ ID NO:1.
[0334] 17. The antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising amino acid residue R338 of SEQ ID NO: 1.
[0335] 18. The antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising amino acid residues R338 and K341 of SEQ ID NO: 1.
[0336] 19. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising two or three of the amino acid residues L337, R338, S339, T340, K341 and T343 of SEQ ID NO:1.
[0337] 20. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising four or five of the amino acid residues L337, R338, S339, T340, K341 and T343 of SEQ ID NO: 1.
[0338] 21. The antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising the following residues:
[0339] SEQ ID NO:1
[0340] a. R338, S339, T340, K341 and T343,
[0341] b.L337, S339, T340, K341 and T343,
[0342] c.L337, R338, T340, K341 and T343,
[0343] d.L337, R338, S339, K341 and T343,
[0344] e.L337, R338, S339, T340 and T343 or
[0345] f.L337, R338, S339, T340 and K341.
[0346] 22. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising amino acid residues L337, R338, S339, T340, K341 and T343 of SEQ ID NO: 1.
[0347] 23. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising one or more of amino acid residues K301, D332, R333, A334, T335, R338 and N346 of SEQ ID NO:1.
[0348] 24. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising amino acid residues L337, R338, S339, T340, K341 and T343 of SEQ ID NO: 1.
[0349] 25. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising two or three of the amino acid residues K301, D332, R333, A334, T335, R338 and N346 of SEQ ID NO:1.
[0350] 26. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising four or five of the amino acid residues K301, D332, R333, A334, T335, R338 and N346 of SEQ ID NO:1.
[0351] 27. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising five or six of the amino acid residues K301, D332, R333, A334, T335, R338 and N346 of SEQ ID NO:1.
[0352] 28. The antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising the following residues:
[0353] SEQ ID NO:1
[0354] a.D332, R333, A334, T335, R338 and N346
[0355] b. K301, R333, A334, T335, R338 and N346
[0356] c. K301, D332, A334, T335, R338 and N346
[0357] d. K301, D332, R333, T335, R338 and N346
[0358] e. K301, D332, R333, A334, R338 and N346
[0359] f. K301, D332, R333, A334, T335 and N346, or
[0360] g. K301, D332, R333, A334, T335 and R338.
[0361] 29. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising amino acid residues D332, R333, L337 and R338 of SEQ ID NO: 1.
[0362] 30. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising amino acid residues K301, D332, R333, A334, T335, R338 and N346 of SEQ ID NO: 1.
[0363] 31. The antibody or antigen-binding fragment thereof according to embodiment 1, wherein the antibody or antigen-binding fragment thereof belongs to "Box 2".
[0364] 32. An antibody or antigen-binding fragment thereof according to embodiment 1, wherein the antibody or antigen-binding fragment thereof competes with a reference antibody, wherein the reference antibody comprises a heavy chain variable domain represented by the sequence of SEQ ID NO: 17 and a light chain variable domain represented by the sequence of SEQ ID NO: 18.
[0365] 33. The antibody according to the preceding embodiment, wherein the reference antibody is a Fab.
[0366] 34. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0367] a. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 17 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 18,
[0368] b. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 85 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 86, or
[0369] c. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO:79 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO:80.
[0370] 35. The antibody or antigen-binding fragment thereof according to embodiment 34, wherein the heavy chain variable domain is at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0371] 36. An antibody or antigen-binding fragment thereof according to embodiment 34, wherein the light chain variable domain is at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0372] 37. An antibody or antigen-binding fragment thereof according to embodiments 35 and 36, wherein the heavy chain variable domain and the light chain variable domain are both at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0373] 38. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0374] a.
[0375] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 17, and
[0376] ii. three light chain variable domain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 18,
[0377] b.
[0378] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 85, and
[0379] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 86, or
[0380] c.
[0381] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 79, and
[0382] ii. three light chain variable domain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 80.
[0383] 39. An antibody or antigen-binding fragment thereof according to embodiment 38, wherein the three heavy chain CDR sequences have at most 9, such as 8, such as 7 or such as 6 amino acid changes compared to the CDRs of the SEQ IDs shown.
[0384] 40. An antibody or antigen-binding fragment thereof according to embodiment 38, wherein the three heavy chain CDR sequences have at most 5, such as 4, such as 3, such as 2 or at most 1 amino acid changes compared to the CDRs of the SEQ IDs shown.
[0385] 41. An antibody or antigen-binding fragment thereof according to embodiment 38, wherein the three light chain CDR sequences have at most 9, such as 8, such as 7 or such as 6 amino acid changes compared to the CDRs of the SEQ IDs shown.
[0386] 42. An antibody or antigen-binding fragment thereof according to embodiment 38, wherein the three light chain CDR sequences have at most 5, such as 4, such as 3, such as 2 or at most 1 amino acid changes compared to the CDRs of the SEQ ID shown.
[0387] 43. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0388] a. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 17, and
[0389] The CDR sequence of the light chain variable domain is represented by SEQ ID NO:18.
[0390] 44. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0391] a. The heavy chain variable domain represented by SEQ ID NO: 17 and the light chain variable domain represented by SEQ ID NO: 18.
[0392] 45. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising one or more of amino acid residues H256, H257, N258, K293, R403, Y404, N406, W407, E410 and K411 of SEQ ID NO:1.
[0393] 46. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising amino acid residues H256, H257, N258, K293, R403, Y404, N406, W407, E410 and K411 of SEQ ID NO:1.
[0394] 47. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising two, three or four residues of amino acid residues H256, H257, N258, K293, R403, Y404, N406, W407, E410 and K411 of SEQ ID NO:1.
[0395] 48. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising five, six or seven of the amino acid residues H256, H257, N258, K293, R403, Y404, N406, W407, E410 and K411 of SEQ ID NO:1.
[0396] 49. An antibody or antigen-binding fragment thereof according to any of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising eight, nine or ten residues of amino acid residues H256, H257, N258, K293, R403, Y404, N406, W407, E410 and K411 of SEQ ID NO:1.
[0397] 50. The antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising the following amino acid residues:
[0398] SEQ ID NO:1
[0399] a.H257, N258, K293, R403, Y404, N406, W407, E410 and K411,
[0400] b. H256, N258, K293, R403, Y404, N406, W407, E410 and K411,
[0401] c.H256, H257, K293, R403, Y404, N406, W407, E410 and K411,
[0402] d.H256, H257, N258, R403, Y404, N406, W407, E410 and K411,
[0403] e.H256, H257, N258, K293, Y404, N406, W407, E410 and K411,
[0404] f.H256, H257, N258, K293, R403, N406, W407, E410 and K411,
[0405] g. H256, H257, N258, K293, R403, Y404, W407, E410 and K411,
[0406] h. H256, H257, N258, K293, R403, Y404, N406, E410 and K411,
[0407] i. H256, H257, N258, K293, R403, Y404, N406, W407, and K411, or
[0408] j. H256, H257, N258, K293, R403, Y404, N406, W407, and E410.
[0409] 51. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising amino acid residues H256, H257, N258, K293, R403, Y404, N406, W407, E410 and K411 of SEQ ID NO:1.
[0410] 52. The antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising amino acid residues H257, K293 and N406 of SEQ ID NO: 1.
[0411] 53. The antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody is a pro-coagulant antibody.
[0412] 54. The antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of increasing the procoagulant activity of FIXa.
[0413] 55. The antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody is capable of increasing the enzymatic activity of FIXa towards FX.
[0414] 56. The antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody is capable of functionally replacing FVIII and / or FVIIIa.
[0415] 57. An antibody or antigen-binding fragment thereof that is capable of binding to FX (SEQ ID NO: 2) or its activated form (FXa).
[0416] 58. The antibody or antigen-binding fragment thereof according to embodiment 57, wherein the antibody or antigen-binding fragment thereof is part of "Box A".
[0417] 59. An antibody or antigen-binding fragment thereof according to embodiment 57, wherein the antibody or antigen-binding fragment thereof competes with a reference antibody, wherein the reference antibody comprises a heavy chain variable domain represented by SEQ ID NO:65 and a light chain variable domain represented by SEQ ID NO:66.
[0418] 60. The antibody according to the preceding embodiment, wherein the reference antibody is a Fab.
[0419] 61. An antibody or antigen-binding fragment thereof according to any of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising one or more of the amino acid residues H101, E103, R113, T116, L117, A118, T127, S227, E228, F229, Y230, E266, R287, L303, P304, E305, L419, K420, D423, R424, M426, K427 and T428 of FX / FXa.
[0420] 62. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising amino acid residues H101, E103, R113, T116, L117, A118, T127, S227, E228, F229, Y230, E266, R287, P304, L303, P304, E305, L419, K420, D423, R424, M426, K427 and T428 of FX / FXa.
[0421] 63. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising one or more of the amino acid residues R113, Y230, K420, D423, R424 and K427 of FX / FXa.
[0422] 64. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof is capable of binding to an epitope comprising amino acid residues R113, Y230, K420, D423, R424 and K427 of FX / FXa.
[0423] 65. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO:65 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO:66.
[0424] 66. An antibody or antigen-binding fragment thereof according to embodiment 65, wherein the heavy chain variable domain is at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0425] 67. An antibody or antigen-binding fragment thereof according to embodiment 65, wherein the light chain variable domain is at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0426] 68. An antibody or antigen-binding fragment thereof according to embodiments 66 and 67, wherein the heavy chain variable domain and the light chain variable domain are both at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0427] 69. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0428] a. three heavy chain CDR sequences having up to 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 65, and
[0429] b. Three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 66.
[0430] 70. An antibody or antigen-binding fragment thereof according to embodiment 69, wherein the three heavy chain CDR sequences have at most 9, such as 8, such as 7 or such as 6 amino acid changes compared to the CDRs of the SEQ IDs shown.
[0431] 71. An antibody or antigen-binding fragment thereof according to embodiment 69, wherein the three heavy chain CDR sequences have at most 5, such as 4, such as 3, such as 2 or at most 1 amino acid changes compared to the CDRs of the SEQ ID shown.
[0432] 72. An antibody or antigen-binding fragment thereof according to embodiment 69, wherein the three light chain CDR sequences have at most 9, such as 8, such as 7 or such as 6 amino acid changes compared to the CDRs of the SEQ IDs shown.
[0433] 73. An antibody or antigen-binding fragment thereof according to embodiment 69, wherein the three light chain CDR sequences have at most 5, such as 4, such as 3, such as 2 or at most 1 amino acid changes compared to the CDR of the SEQ ID shown.
[0434] 74. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises the CDR sequence of the heavy chain variable domain represented by SEQ ID NO:65 and the CDR sequence of the light chain variable domain represented by SEQ ID NO:66.
[0435] 75. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable domain represented by SEQ ID NO:65 and a light chain variable domain represented by SEQ ID NO:66.
[0436] 76. The antibody or antigen-binding fragment thereof according to embodiment 57, wherein the antibody or antigen-binding fragment thereof is part of "Box B".
[0437] 77. An antibody or antigen-binding fragment thereof according to embodiment 57, wherein the antibody or antigen-binding fragment thereof competes with a reference antibody, wherein the reference antibody comprises a heavy chain variable domain represented by SEQ ID NO:67 and a light chain variable domain represented by SEQ ID NO:68.
[0438] 78. The antibody or antigen-binding fragment thereof according to the preceding embodiment, wherein the reference antibody is a Fab.
[0439] 79. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0440] a. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 67 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 68,
[0441] b. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 23 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 24,
[0442] c. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 39 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 40, or
[0443] d. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO:59 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO:60.
[0444] 80. An antibody or antigen-binding fragment thereof according to embodiment 79, wherein the heavy chain variable domain is at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0445] 81. An antibody or antigen-binding fragment thereof according to embodiment 79, wherein the light chain variable domain is at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0446] 82. An antibody or antigen-binding fragment thereof according to embodiments 80 and 81, wherein the heavy chain variable domain and the light chain variable domain are both at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0447] 83. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0448] a.
[0449] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 67, and
[0450] ii. three light chain variable domain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 68,
[0451] b.
[0452] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 23, and
[0453] ii. three light chain variable domain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 24,
[0454] c.
[0455] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 39, and
[0456] ii. three light chain variable domain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 40, or
[0457] d.
[0458] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 59, and
[0459] ii. three light chain variable domain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 60.
[0460] 84. An antibody or antigen-binding fragment thereof according to embodiment 83, wherein the three heavy chain CDR sequences have at most 9, such as 8, such as 7 or such as 6 amino acid changes compared to the CDRs of the SEQ IDs shown.
[0461] 85. An antibody or antigen-binding fragment thereof according to embodiment 83, wherein the three heavy chain CDR sequences have at most 5, such as 4, such as 3, such as 2 or at most 1 amino acid changes compared to the CDRs of the SEQ ID shown.
[0462] 86. An antibody or antigen-binding fragment thereof according to embodiment 83, wherein the three light chain CDR sequences have at most 9, such as 8, such as 7 or such as 6 amino acid changes compared to the CDRs of the SEQ ID shown.
[0463] 87. An antibody or antigen-binding fragment thereof according to embodiment 83, wherein the three light chain CDR sequences have at most 5, such as 4, such as 3, such as 2 or at most 1 amino acid changes compared to the CDR of the SEQ ID shown.
[0464] 88. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0465] a. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 67 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 68,
[0466] b. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 23 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 24,
[0467] c. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 39 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 40, or
[0468] d. The CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 59 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 60.
[0469] 89. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0470] a. a heavy chain variable domain represented by SEQ ID NO: 67 and a light chain variable domain represented by SEQ ID NO: 68,
[0471] b. a heavy chain variable domain represented by SEQ ID NO: 23 and a light chain variable domain represented by SEQ ID NO: 24,
[0472] c. a heavy chain variable domain represented by SEQ ID NO: 39 and a light chain variable domain represented by SEQ ID NO: 40, or
[0473] d. The heavy chain variable domain represented by SEQ ID NO:59 and the light chain variable domain represented by SEQ ID NO:60.
[0474] 90. The antibody or antigen-binding fragment thereof according to embodiment 57, wherein the antibody or antigen-binding fragment thereof is part of "Box C".
[0475] 91. An antibody or antigen-binding fragment thereof according to embodiment 57, wherein the antibody or antigen-binding fragment thereof competes with a reference antibody, wherein the reference antibody comprises a heavy chain variable domain represented by SEQ ID NO:21 and a light chain variable domain represented by SEQ ID NO:22.
[0476] 92. The antibody or antigen-binding fragment thereof according to the preceding embodiment, wherein the reference antibody is a Fab.
[0477] 93. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0478] a. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 21 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 22,
[0479] b. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 25 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 26,
[0480] c. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 27 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 28,
[0481] d. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 29 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 30,
[0482] e. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 31 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 32,
[0483] f. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 33 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 34,
[0484] g. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 35 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 36,
[0485] h. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 37 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 38,
[0486] i. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 39 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 40,
[0487] j. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO:41 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO:42,
[0488] k. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 43 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 44,
[0489] 1. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 51 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 52,
[0490] m. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 53 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 54,
[0491] n. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 55 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 56,
[0492] o. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 57 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 58,
[0493] p. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 59 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 60,
[0494] q. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 61 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 62, or
[0495] r. A heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO:63 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO:64.
[0496] 94. An antibody or antigen-binding fragment thereof according to embodiment 93, wherein the heavy chain variable domain is at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0497] 95. An antibody or antigen-binding fragment thereof according to embodiment 93, wherein the light chain variable domain is at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0498] 96. An antibody or antigen-binding fragment thereof according to embodiments 94 and 95, wherein the heavy chain variable domain and the light chain variable domain are both at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0499] 97. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0500] a.
[0501] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 21, and
[0502] ii. three light chain variable domain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 22,
[0503] b.
[0504] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 25, and
[0505] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 26,
[0506] c.
[0507] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 27, and
[0508] ii. three light chain variable domain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 28, or
[0509] d.
[0510] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 29, and
[0511] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 30, e.
[0512] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 31, and
[0513] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 32, f.
[0514] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 33, and
[0515] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 34, g.
[0516] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 35, and
[0517] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 36, or
[0518] h.
[0519] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 37, and
[0520] ii. Three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 38
[0521] i.
[0522] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 39, and
[0523] ii. three light chain variable domain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 40, j.
[0524] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 41, and
[0525] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO:42, k.
[0526] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 43, and
[0527] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 44, or
[0528] l.
[0529] m.
[0530] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 51, and
[0531] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 52, or
[0532] n.
[0533] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 53, and
[0534] Three light chain CDR sequences having up to 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 54
[0535] o.
[0536] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 55, and
[0537] ii. Three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 56
[0538] p.
[0539] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 57, and
[0540] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 58,
[0541] q.
[0542] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 59, and
[0543] ii. three light chain variable domain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 60,
[0544] r.
[0545] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 61, and
[0546] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 62, or
[0547] s.
[0548] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 63, and
[0549] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 64.
[0550] 98. An antibody or antigen-binding fragment thereof according to embodiment 97, wherein the three heavy chain CDR sequences have at most 9, such as 8, such as 7 or such as 6 amino acid changes compared to the CDRs of the SEQ IDs shown.
[0551] 99. An antibody or antigen-binding fragment thereof according to embodiment 97, wherein the three heavy chain CDR sequences have at most 5, such as 4, such as 3, such as 2 or at most 1 amino acid changes compared to the CDRs of the SEQ IDs shown.
[0552] 100. An antibody or antigen-binding fragment thereof according to embodiment 97, wherein the three light chain CDR sequences have at most 9, such as 8, such as 7 or such as 6 amino acid changes compared to the CDRs of the SEQ IDs shown.
[0553] 101. An antibody or antigen-binding fragment thereof according to embodiment 97, wherein the three light chain CDR sequences have at most 5, such as 4, such as 3, such as 2 or at most 1 amino acid changes compared to the CDR of the SEQ ID shown.
[0554] 102. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0555] a. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 21 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 22,
[0556] b. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 25 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 26,
[0557] c. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 27 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 28,
[0558] d. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 29 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 30,
[0559] e. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 31 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 32,
[0560] f. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 33 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 34,
[0561] g. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 35 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 36,
[0562] h. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 37 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 38,
[0563] i. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 39 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 40,
[0564] j. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 41 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 42,
[0565] k. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 43 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 44,
[0566] 1. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 51 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 52,
[0567] m. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 53 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 54,
[0568] n. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 55 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 56,
[0569] o. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 57 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 58,
[0570] p. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 59 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 60,
[0571] q. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 61 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 62, or
[0572] r. The CDR sequence of the heavy chain variable domain represented by SEQ ID NO:63 and the CDR sequence of the light chain variable domain represented by SEQ ID NO:64.
[0573] 103. The antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain represented by the following sequences:
[0574] Variable domains and light chain variable domains:
[0575] a. SEQ ID NO: 21 and 22,
[0576] b. SEQ ID NO: 25 and 26,
[0577] c. SEQ ID NO: 27 and 28,
[0578] d. SEQ ID NO: 29 and 30,
[0579] e. SEQ ID NO:31 and 32,
[0580] f. SEQ ID NO: 33 and 34,
[0581] g. SEQ ID NO:35 and 36,
[0582] h. SEQ ID NO: 37 and 38,
[0583] i. SEQ ID NO: 39 and 40,
[0584] j. SEQ ID NO: 41 and 42,
[0585] k. SEQ ID NO: 43 and 44,
[0586] 1. SEQ ID NO: 51 and 52,
[0587] m. SEQ ID NO: 53 and 54,
[0588] n. SEQ ID NO: 55 and 56,
[0589] o. SEQ ID NO: 57 and 58,
[0590] p. SEQ ID NO: 59 and 60,
[0591] q. SEQ ID NO: 61 and 62, or
[0592] r. SEQ ID NO:63 and 64.
[0593] 104. The antibody or antigen-binding fragment thereof according to embodiment 57, wherein the antibody or antigen-binding fragment thereof belongs to "Box D".
[0594] 105. An antibody or antigen-binding fragment thereof according to embodiment 57, wherein the antibody or antigen-binding fragment thereof competes with a reference antibody, wherein the reference antibody comprises a heavy chain variable domain represented by SEQ ID NO:47 and a light chain variable domain represented by SEQ ID NO:48.
[0595] 106. The antibody according to the preceding embodiment, wherein the reference antibody is a Fab.
[0596] 107. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0597] a. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 47 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 48,
[0598] b. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 45 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 46,
[0599] c. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 51 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO: 52,
[0600] or
[0601] d. a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO:61 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO:62.
[0602] 108. An antibody or antigen-binding fragment thereof according to embodiment 107, wherein the heavy chain variable domain is at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0603] 109. An antibody or antigen-binding fragment thereof according to embodiment 107, wherein the light chain variable domain is at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0604] 110. An antibody or antigen-binding fragment thereof according to embodiments 108 and 109, wherein the heavy chain variable domain and the light chain variable domain are both at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0605] 111. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0606] a.
[0607] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 47, and
[0608] ii. three light chain variable domain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 48,
[0609] b.
[0610] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 45, and
[0611] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 46,
[0612] c.
[0613] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 51, and
[0614] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 52, or
[0615] d.
[0616] i. three heavy chain CDR sequences having at most 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 61, and
[0617] ii. three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 62.
[0618] 112. An antibody or antigen-binding fragment thereof according to embodiment 111, wherein the three heavy chain CDR sequences have at most 9, such as 8, such as 7 or such as 6 amino acid changes compared to the CDRs of the SEQ IDs shown.
[0619] 113. An antibody or antigen-binding fragment thereof according to embodiment 111, wherein the three heavy chain CDR sequences have at most 5, such as 4, such as 3, such as 2 or at most 1 amino acid changes compared to the CDRs of the SEQ ID shown.
[0620] 114. An antibody or antigen-binding fragment thereof according to embodiment 111, wherein the three light chain CDR sequences have at most 9, such as 8, such as 7 or such as 6 amino acid changes compared to the CDRs of the SEQ IDs shown.
[0621] 115. An antibody or antigen-binding fragment thereof according to embodiment 111, wherein the three light chain CDR sequences have at most 5, such as 4, such as 3, such as 2 or at most 1 amino acid changes compared to the CDRs of the SEQ ID shown.
[0622] 116. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0623] a. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 47 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 48,
[0624] b. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 45 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 46,
[0625] c. the CDR sequence of the heavy chain variable domain represented by SEQ ID NO: 51 and the CDR sequence of the light chain variable domain represented by SEQ ID NO: 52,
[0626] or
[0627] d. The CDR sequence of the heavy chain variable domain represented by SEQ ID NO:61 and the CDR sequence of the light chain variable domain represented by SEQ ID NO:62.
[0628] 117. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0629] a. a heavy chain variable domain represented by SEQ ID NO: 47 and a light chain variable domain represented by SEQ ID NO: 48,
[0630] b. a heavy chain variable domain represented by SEQ ID NO: 45 and a light chain variable domain represented by SEQ ID NO: 46,
[0631] c. a heavy chain variable domain represented by SEQ ID NO: 51 and a light chain variable domain represented by SEQ ID NO: 52,
[0632] or
[0633] d. The heavy chain variable domain represented by SEQ ID NO:61 and the light chain variable domain represented by SEQ ID NO:62.
[0634] 118. The antibody or antigen-binding fragment thereof according to embodiment 57, wherein the antibody or antigen-binding fragment thereof belongs to "Box E".
[0635] 119. An antibody or antigen-binding fragment thereof according to embodiment 57, wherein the antibody or antigen-binding fragment thereof competes with a reference antibody, wherein the reference antibody comprises a heavy chain variable domain represented by SEQ ID NO:49 and a light chain variable domain represented by SEQ ID NO:50.
[0636] 120. The antibody according to the preceding embodiment, wherein the reference antibody is a Fab.
[0637] 121. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO:49 and a light chain variable domain that is at least 90% identical to the sequence represented by SEQ ID NO:50.
[0638] 122. An antibody or antigen-binding fragment thereof according to embodiment 121, wherein the heavy chain variable domain is at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0639] 123. An antibody or antigen-binding fragment thereof according to embodiment 121, wherein the light chain variable domain is at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0640] 124. An antibody or antigen-binding fragment thereof according to embodiments 122 and 123, wherein the heavy chain variable domain and the light chain variable domain are both at least 92%, 94%, 96% or 98% identical to the SEQ ID shown.
[0641] 125. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises
[0642] a. three heavy chain CDR sequences having up to 10 amino acid changes compared to the heavy chain variable domain CDR sequence represented by SEQ ID NO: 49, and
[0643] b. Three light chain CDR sequences having at most 10 amino acid changes compared to the light chain variable domain CDR sequence represented by SEQ ID NO: 50.
[0644] 126. An antibody or antigen-binding fragment thereof according to embodiment 125, wherein the three heavy chain CDR sequences have at most 9, such as 8, such as 7 or such as 6 amino acid changes compared to the CDRs of the SEQ IDs shown.
[0645] 127. An antibody or antigen-binding fragment thereof according to embodiment 125, wherein the three heavy chain CDR sequences have at most 5, such as 4, such as 3, such as 2 or at most 1 amino acid changes compared to the CDRs of the SEQ ID shown.
[0646] 128. An antibody or antigen-binding fragment thereof according to embodiment 125, wherein the three light chain CDR sequences have at most 9, such as 8, such as 7 or such as 6 amino acid changes compared to the CDRs of the SEQ ID shown.
[0647] 129. An antibody or antigen-binding fragment thereof according to embodiment 125, wherein the three light chain CDR sequences have at most 5, such as 4, such as 3, such as 2 or at most 1 amino acid changes compared to the CDR of the SEQ ID shown.
[0648] 130. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises the CDR sequence of the heavy chain variable domain represented by SEQ ID NO:49 and the CDR sequence of the light chain variable domain represented by SEQ ID NO:50.
[0649] 131. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable domain represented by SEQ ID NO:49 and a light chain variable domain represented by SEQ ID NO:50.
[0650] 132. A multispecific antibody or antigen-binding fragment thereof that is capable of binding to FIX / FIXa and FX / FXa.
[0651] 133. A multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody comprises an antigen-binding fragment according to any one of the preceding embodiments 1-131.
[0652] 134. A multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody comprises an antigen-binding fragment according to any one of the preceding embodiments 2-30.
[0653] 135. A multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody comprises an antigen-binding fragment according to any one of the preceding embodiments 31-52.
[0654] 136. A multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody comprises an antigen-binding fragment according to any one of the preceding embodiments 57-131.
[0655] 137. A multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody comprises an antigen-binding fragment according to any one of the preceding embodiments 58-75.
[0656] 138. A multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody comprises an antigen-binding fragment according to any one of the preceding embodiments 76-89.
[0657] 139. A multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody comprises an antigen-binding fragment according to any one of the preceding embodiments 90-103.
[0658] 140. A multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody comprises an antigen-binding fragment according to any one of the preceding embodiments 104-117.
[0659] 141. A multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody comprises an antigen-binding fragment according to any one of the preceding embodiments 118-131.
[0660] 142. A multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody comprises an antigen-binding fragment according to any one of the preceding embodiments 1-56, and an antigen-binding fragment according to any one of the preceding embodiments 57-131.
[0661] 143. A multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody comprises an antigen-binding fragment according to any one of the preceding embodiments 2-30, and an antigen-binding fragment according to any one of the preceding embodiments 58-75.
[0662] 144. A multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody comprises an antigen-binding fragment according to any one of the preceding embodiments 2-30, and an antigen-binding fragment according to any one of the preceding embodiments 76-89.
[0663] 145. A multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody comprises an antigen-binding fragment according to any one of the preceding embodiments 2-30, and an antigen-binding fragment according to any one of the preceding embodiments 90-103.
[0664] 146. A multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody comprises an antigen-binding fragment according to any one of the preceding embodiments 31-52, and an antigen-binding fragment according to any one of the preceding embodiments 58-75.
[0665] 147. A multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody comprises an antigen-binding fragment according to any one of the preceding embodiments 31-52, and an antigen-binding fragment according to any one of the preceding embodiments 76-89.
[0666] 148. A multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody comprises an antigen-binding fragment according to any one of the preceding embodiments 31-52, and an antigen-binding fragment according to any one of the preceding embodiments 90-103.
[0667] 149. The multispecific antibody or antigen-binding fragment thereof according to embodiment 132, wherein the antibody is a bispecific antibody capable of specifically binding to FIX / FIXa and FX / FXa, wherein the binding domain is derived from mAb1-1371 / mAb1-1307, mAb1-6705 / mAb1-1307, mAb1-1371 / mAb0-1886, mAb1-7441 / mAb0-1886, mAb1-7447 / mAb0-1886, mAb1-7481 / mAb0-1886, mAb1-1371 / mAb0-1998, mAb1-6716 / mAb0-1998, mAb1-6723 / mAb0-1998, mAb1-6730 / mAb0-1998 , mAb1-6731 / mAb0-1998, mAb1-6737 / mAb0-1998, mAb1-6754 / mAb0-1998, mAb1-7378 / mAb0-1998, mAb1-7441 / mAb0-1998, mAb1-7447 / mAb0-1998, mAb / mAb0-1998, mAb1-6723 / mAb1-1307, mAb1-6723 / mAb0-1886, mAb1-6705 / mAb0-1886, mAb1-7481 / mAb0-1998 and mAb1-6705 / mAb0-1998.
[0668] 150. The antibody or antigen-binding fragment thereof according to any one of embodiments 132-149, wherein the antibody is a pro-coagulant bispecific antibody.
[0669] 151. The antibody or antigen-binding fragment thereof according to any one of embodiments 132-149, wherein the antibody is a bispecific antibody capable of increasing the procoagulant activity of FIXa.
[0670] 152. The antibody or antigen-binding fragment thereof according to any one of embodiments 132-149, wherein the antibody is a bispecific antibody capable of increasing the enzymatic activity of FIXa on FX.
[0671] 153. The antibody or antigen-binding fragment thereof according to any one of embodiments 132-149, wherein the antibody is a bispecific antibody capable of functionally replacing FVIII and / or FVIIIa.
[0672] 154. A multispecific antibody capable of stimulating the enzymatic activity of FIXa on FX, comprising a first antigen binding site that recognizes FIX (SEQ ID NO: 1) or an activated form thereof (FIXa) and a second antigen binding site that recognizes FX (SEQ ID NO: 2) or an activated form thereof (FXa), wherein
[0673] a) the first antigen binding site comprises a CDR of an antibody selected from mAb1-5743, mAb1-6584, mAb1-8768, mAb1-6037, mAb1-6081, mAb1-4857, mAb1-8780, mAb1-9016, mAb1-9015, mAb1-8467, mAb1-5783, or mAb1-5781, and
[0674] b) the second antigen binding site comprises the CDRs of an antibody selected from mAb1-6738, mAb1-6463, mAb1-6723, mAb1-7503 or mAb1-6097.
[0675] 155. A multispecific antibody capable of stimulating the enzymatic activity of FIXa on FX, comprising
[0676] a first polypeptide that recognizes FIX / FIXa, and
[0677] A second polypeptide that recognizes FX / FXa, wherein
[0678] a) the first polypeptide comprises the heavy chain variable domain and the light chain variable domain of mAb1-5743, mAb1-6584, mAb1-8768, mAb1-6037, mAb1-6081, mAb1-4857, mAb1-8780, mAb1-9016, mAb1-9015, mAb1-8467, mAb1-5783 or mAb1-5781, and
[0679] b) the second polypeptide comprises the heavy chain variable domain and the light chain variable domain of mAb1-6738, mAb1-6463, mAb1-6723, mAb1-7503 or mAb1-6097.
[0680] 156. The antibody according to any one of embodiments 154 or 155, wherein the antibody is a bispecific antibody.
[0681] 157. An antibody according to any one of embodiments 150-156, wherein the stimulation of the enzymatic activity of FX by FIXa is determined in a FXa generation assay as described herein using a monovalent one-armed anti-FIX / FIXa antibody, wherein the stimulation index is at least 94, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 3000, 4000 or 5000-fold when measured using a one-armed antibody concentration that results in at least 80% saturation of FIXa.
[0682] 158. A multispecific antibody capable of stimulating the enzymatic activity of FIXa on FX, comprising
[0683] A first antigen binding site that recognizes FIX (SEQ ID NO: 1) or an activated form thereof (FIXa) and a second antigen binding site that recognizes FX (SEQ ID NO: 2) or an activated form thereof (FXa), wherein
[0684] The first antigen binding site is capable of specifically binding to an epitope comprising amino acid residue R338 of FIX / FIXa, and
[0685] The second antigen binding site is capable of binding to the EGF-2 domain and / or the catalytic subunit of FX / FXa.
[0686] 159. The multispecific antibody according to embodiment 158, wherein
[0687] The first antigen binding site is capable of specifically binding to an epitope comprising amino acid residues R338 and K341 of FIX / FIXa.
[0688] 160. The multispecific antibody according to embodiment 159, wherein
[0689] The first antigen binding site is capable of specifically binding to an epitope comprising amino acid residues L337, R338, S339, T340, K341 and T343 of FIX / FIXa.
[0690] 161. A multispecific antibody capable of stimulating the enzymatic activity of FIXa on FX, comprising a first antigen binding site that recognizes FIX (SEQ ID NO: 1) or its activated form FIXa and a second antigen binding site that recognizes FX (SEQ ID NO: 2) or its activated form (FXa)
[0691] in
[0692] The first antigen binding site is capable of specifically binding to an epitope comprising amino acid residues D332, R333, L337 and R338 of FIX / FIXa, and
[0693] The second antigen binding site is capable of binding to the EGF-2 domain and / or the catalytic subunit of FX / FXa.
[0694] 162. The multispecific antibody according to embodiment 161, wherein
[0695] The first antigen binding site is capable of specifically binding to an epitope comprising amino acid residues K301, D332, R333, A334, T335, R338, and N346 of FIX / FIXa.
[0696] 163. A multispecific antibody capable of stimulating the enzymatic activity of FIXa on FX, comprising
[0697] Recognizes the first antigen binding site of FIX / FIXa, and
[0698] Recognizes the second antigen binding site of FX / FXa
[0699] in
[0700] The first antigen binding site is capable of specifically binding to an epitope comprising amino acid residues H257, K293 and N406 of FIX / FIXa, and
[0701] The second antigen binding site is capable of binding to the EGF-2 domain and / or the catalytic subunit of FX / FXa.
[0702] 164. An antibody according to any one of embodiments 1-56 and 132-156, wherein the stimulation of the enzymatic activity of FX by FIXa is measured in a FXa generation assay as described herein using a monovalent one-armed anti-FIX / FIXa antibody, wherein the stimulation index is at least 94, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 3000, 4000 or 5000 times when measured using a one-armed antibody concentration that results in at least 80% saturation of FIXa.
[0703] 165. The antibody according to any one of embodiments 1-56 and 132-156, wherein the stimulation of the enzymatic activity of FX by FIXa is measured in a FXa generation assay as described herein using a monovalent one-armed anti-FIX / FIXa antibody, wherein the stimulation index is 50-5000 fold, such as 94 to 2500 fold, such as 100 to 2500 fold, such as 200 to 300 fold when measured using a one-armed antibody concentration that results in at least 80% saturation of FIXa. To 2500 times, such as 300 to 2500 times, such as 400 to 2500 times, such as 500 to 2500 times, such as 600 to 2500 times, such as 700 to 2500 times, such as 800 to 2500 times, such as 500 to 2500 times, such as 600 to 2500 times, such as 700 to 2500 times, such as 800 to 2500 times, such as 900 to 2500 times, such as 1000 to 2500 times, or such as 1500 to 2500 times.
[0704] 166. The antibody according to any one of the preceding embodiments, wherein the antibody is a pro-coagulant antibody.
[0705] 167. An antibody according to any one of the preceding embodiments, wherein the antibody functionally replaces FVIII and / or FVIIIa.
[0706] 168. The antibody according to any one of the preceding embodiments, wherein the antibody is a bispecific antibody.
[0707] 169. The antibody according to any one of the preceding embodiments, wherein the antibody isotype is IgGl, IgG2, IgG3 or IgG4 or a combination thereof.
[0708] 170. An antibody according to any one of embodiments 57-131, wherein the light chain variable domain of the antibody or antigen-binding fragment thereof comprises amino acid residues R57, R96 (SEQ ID NO:22), and wherein the heavy chain variable domain of the antibody comprises amino acid residues W33, D52, D55, H100, Y101, Y102, H103 (SEQ ID NO:21).
[0709] 171. An antibody or antigen-binding fragment thereof according to any one of the preceding embodiments, for use in a method for treating a coagulopathy or coagulation disorder.
[0710] 172. A pharmaceutical composition comprising an antibody or antigen-binding fragment thereof according to any one of the preceding embodiments for use in the treatment of a coagulopathy or coagulation disorder.
[0711] 173. A method of treating a subject having a coagulopathy or coagulation disorder, comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of the preceding embodiments.
[0712] 174. The method of embodiment 173, wherein the coagulopathy or coagulation disorder is hemophilia A or hemophilia A with inhibitors. Example
[0713] List of abbreviations
[0714] ACN: Acetonitrile
[0715] CDR: Complementarity determining region
[0716] EGR-CK: EGR-Chloromethyl Ketone
[0717] LC-MS: Liquid chromatography-mass spectrometry
[0718] FACS: Fluorescence activated cell sorting
[0719] FIX: Coagulation Factor IX
[0720] FIXa: Coagulation Factor IXa
[0721] FX: Coagulation factor X.
[0722] FXa: Coagulation Factor Xa
[0723] HA: Hemophilia A
[0724] HA-PPP: HA-induced human platelet-poor plasma
[0725] HA-PRP: HA-induced human platelet-rich plasma
[0726] hFIXa: human coagulation factor IXa
[0727] ITC: Isothermal Titration Calorimetry
[0728] MACS: Magnetic Activated Cell Sorting
[0729] OA: Single Arm
[0730] PCR: polymerase chain reaction
[0731] SPR: Surface Plasmon Resonance
[0732] Example 1: Development of Factor IX / FIXa Fab and mAb expression plasmids
[0733] Various antibody development methods were used to identify FIX / FIXa binding antibodies as disclosed herein. To generate a diverse panel of antibodies against FIXa and FX, immunization of mice and rabbits and selection based on phage display and Adimab yeast display were performed.
[0734] Adimab yeast display
[0735] The Adimab platform is a yeast display system that includes a fully human naive IgG1 / kappa library with a diversity of 10 10 , and covers 20 of the 42 VH families. The antibody phage display platform used is a proprietary fully human Fab display library. The size of the library is 10 10 , and constructed by a combined method utilizing chemical synthesis of light chain and heavy chain CDR1 and CDR2 and supplemented with PCR amplification of heavy chain CDR3 from human peripheral blood mononuclear cells. The antibody selection process is guided by a method based on MACS and FACS, which allows real-time monitoring of the applied selection criteria. Since the selection is based on MACS and FACS, a labeled antigen (e.g., biotin) is required. The hFIXa (FIXa-EGR-biotin) or antibody-mediated hFIXa fixation using biotin-labeled active site inhibition is selected for activity. The binding of hits is evaluated using Bio-layer interferometry (Octet fortebio system).
[0736] Phage display
[0737] To maximize coverage of epitope diversity, different panning strategies were explored, including panning with biotinylated FIXa-EGR, FX, active site inhibited FXa, or antigen capture using anti-FIXa antibodies. Initial hits were identified by phage ELISA. After sequence analysis, unique hits were cloned, expressed as IgG1, and ranked using SPR (Biacore) or Bio-layer interferometry (Octet fortebio systems).
[0738] In vivo platform
[0739] To generate fully human antibodies in mice, use Kymouse TM Mouse HK and HL 1.0 (κ and λ chains were used, respectively). Additional immunizations were performed in wild-type mice and rabbits to maximize antibody diversity.
[0740] Generation of anti-FIXa antibodies
[0741] Using standard protocols, mice or rabbits were immunized with FIXa, FIXa-EGR or FX. Antibodies produced in mice or rabbits were screened by ELISA. FIXa binding rabbit B cells were sorted by FACS using random biotinylated FIXa-EGR. Antibody hits from rabbits and mice were recombinantly expressed (rabbit mAb) or amplified (mouse hybridoma), and antibodies were subsequently purified on a small scale.
[0742] Generation of anti-FX antibodies
[0743] Kymouse mice and rabbits were immunized with FX using standard or repeated immunization at multiple sites (RIMMS) protocols. Rabbit B cells were isolated by FACS sorting using randomly biotinylated FX. Anti-FX mAbs from fusions and sorting were screened using ELISA and the Octet fortebio system. Sequencing of Kymouse and wt mouse derived antibodies
[0744] Hybridomas producing anti-FIXa and anti-FX antibodies derived from Kymouse mice or wt mice were sequenced and expressed in HEK293 cells using standard techniques. Binding of the expressed antibodies was evaluated using the Octet fortebio system.
[0745] The variable domain (V H and V L) encoding DNA sequence was inserted into a pTT-based mammalian expression vector (Durocher et al. (2002) Nucleic Acid Res. 30: E9) or into a pcDNA3.4 mammalian expression vector (Invitrogen) containing a DNA sequence encoding the antibody constant region. For the pTT / pcDNA3.4 mAb expression vector, V H and V L DNA sequences were compared with human IgG1 or IgG 4 S228P(C H 1C H 2C H 3) or person C L The kappa constant region encoding DNA sequence was inserted in frame. H DNA sequence and human IgG 1 C H 1 The coding DNA sequence is inserted in frame.
[0746] For the 224F3 reference compound used in Examples 6, 8 and 18 below, 224F3V H and V L The sequences were obtained from EP1660536B1 (SEQ ID NOs: 1 and 2, respectively). 224F3V H and V L The coding DNA sequences were respectively identical to those of human IgG1 (C H 1C H 2C H 3) or person C L The kappa constant region encoding DNA sequence was inserted in frame into a mammalian expression vector based on pTT5 / pcDNA3.4.
[0747] All expression vectors included a 5' DNA sequence containing a kozak sequence and a DNA sequence encoding a signal peptide in frame with the antibody encoding DNA sequence.
[0748] Example 2: Recombinant expression of antibodies and antibody Fab fragments
[0749] Essentially following the manufacturer's instructions, transient transfection of HEK293 suspension cells (293Expi, Invitrogen) was used to express antibodies and antibody Fab fragments. 293Expi cells were usually subcultured every 3-4 days in Expi293F expression medium (Invitrogen, catalog number A1435104) supplemented with 1% P / S (GIBCO catalog number 15140-122). Expi293F cells were transfected at a cell density of 2.5-3 mill / mL using Expifectamine. For each liter of Expi293F cells, a total of 1 mg of plasmid DNA (1:1 ratio of V H -C H 1 (for Fab) or V H -C H 1-C H 2-C H 3 (for mAb) and LC plasmid) were diluted into 50 mL Optimem (GIBCO, catalog number 51985-026, diluent A) and 2.7 mL Expifectamine was diluted into 50 mL Optimem (diluent B) for transfection. For co-transfection of Fab and mAb production, V H -C H 1 and LC plasmid (Fab) and V H -C H 1-C H 2-C H 3 and LC plasmid (mAb). Diluents A and B were mixed and incubated at room temperature for 10-20 minutes. Afterwards, the transfection mixture was added to Expi293F cells, and the cells were incubated at 37°C in a humid incubator under orbital rotation (85-125rpm). One day after transfection, 5ml ExpiFectamine 293 transfection enhancer 1 and 50ml ExpiFectamine 293 transfection enhancer 2 were supplemented to the transfected cells. Cell culture supernatant was generally harvested by centrifugation and then filtration 4-5 days after transfection.
[0750] Example 3: Purification and characterization of Fab and antibodies
[0751] Fab purification and characterization
[0752] Purification of the Fab molecules was performed following a two-step process consisting of affinity chromatography using kappaSelect resin (GE Healthcare, catalog number 17-5458-11) and size exclusion chromatography using Superdex200 resin (GE Healthcare, catalog number 17-1043-04). Chromatographic system (GE Healthcare, catalog number 18-1112-41) is purified. The buffer system for affinity purification step is a balance buffer composed of 20mM sodium phosphate pH 7.2, 150mM NaCl and an elution buffer composed of 10mM formic acid pH 3.5 and a pH adjustment buffer composed of 0.4M sodium phosphate pH 9.0. The cell supernatant is directly loaded onto the pre-equilibrium kappaSelect SuRe column without any adjustment. The column is washed with 10 times the column volume of balance buffer, and the Fab molecules are isocratically eluted with about 5 times the column volume of elution buffer. Immediately after elution, the pH of the combined fractions is adjusted to neutral using the pH adjustment buffer. The gel filtration resin pre-filled in the column is used to further purify the Fab molecules and perform buffer exchange. The running buffer for size exclusion chromatography is 25mM HEPES and 150mM NaCl, pH 7.4. The Fab molecules are eluted as a single peak at about 0.5 column volumes. Fractions covering this peak were analyzed using a size exclusion high performance liquid chromatography (SE-HPLC) method setup on an Agilent LC 1100 / 1200 system using a BIOSep-SEC-S3000 300×7.8 mm column (Phenomenex, catalog number 00H-2146-K0) and a running buffer consisting of 200 mM sodium phosphate pH 6.9, 300 mM NaCl, and 10% isopropanol. Based on the analysis, fractions were pooled to obtain a homogenous protein preparation. The final preparation eluted as a single symmetrical peak at a retention time of approximately 10 min at a flow rate of 1 ml / min.
[0753] The purified Fab molecules were further characterized using SDS-PAGE / Coomassie and liquid chromatography mass spectrometry. SDS-PAGE / Coomassie analysis was performed using NuPage 4-12% Bis-Tris gel (Invitrogen, catalog number NP0321BOX). All Fab molecules showed the expected light chain and heavy chain components. The complete molecular weight was determined using a liquid chromatography electrospray ionization time-of-flight mass spectrometry setup on an Agilent 6210 instrument and a desalting column MassPREP (Waters, catalog number USRM10008656). The buffer system used was a LC-MS grade-H 2The Fab fragments were purified by HPLC-HPLC. The final protein concentration was determined by elution buffer consisting of 0.1% formic acid in LC-MS grade ACN and 0.1% formic acid in LC-MS grade ACN. All Fab molecules showed the expected intact molecular weight consistent with the sequence. The final purity was determined based on SE-HPLC analysis. The purity estimates of different Fab fragments were between 95-99%. To determine the final protein concentration, absorbance measurements at 280 nm were performed using a NanoDrop spectrophotometer (Thermo Scientific), and the concentration was calculated using the specific extinction coefficient for each Fab molecule.
[0754] Antibody purification and characterization
[0755] Antibody purification was performed by affinity chromatography using Protein A MabSelect SuRe resin (GE Healthcare, Cat. No. 17-5438-01). The antibody was purified by chromatography system (GE Healthcare, catalog number 18-1112-41). The buffer system used for the affinity purification step was an equilibrium buffer consisting of 20 mM sodium phosphate pH 7.2, 150 mM NaCl and an elution buffer consisting of 10 mM formic acid pH 3.5 and a pH adjustment buffer consisting of 0.4 M sodium phosphate pH 9.0. The cell supernatant was directly loaded onto the pre-equilibrated MabSelect SuRe column without any adjustment. The column was washed with 10 column volumes of equilibrium buffer, and the antibody was isocratically eluted with about 2-5 column volumes of elution buffer. The pH of the combined fractions was adjusted to neutral using the pH adjustment buffer immediately after elution.
[0756] The purified antibodies were characterized using SDS-PAGE / Coomassie, size exclusion high pressure liquid chromatography (SE-HPLC) and liquid chromatography mass spectrometry (LC-MS) analysis. SDS-PAGE / Coomassie analysis was performed using NuPage 4-12% Bis-Tris gel (Invitrogen, catalog number NP0321BOX). Here, all antibodies showed the expected light chain and heavy chain components. The complete molecular weight determination was performed using a liquid chromatography electrospray ionization time-of-flight mass spectrometry setup on an Agilent 6210 instrument and a desalting column MassPREP (Waters, catalog number USRM10008656). The buffer system used was prepared by HPLC-MS grade-H 2The elution buffer was composed of 0.1% formic acid in 0.5% iodine and 0.1% formic acid in LC-MS grade-ACN. The analysis was performed with and without N-glycosidase F (Roche Diagnostics, catalog number 11365177001) and a reducing agent (i.e., mercaptoethanol or DTT). All antibodies showed the expected complete molecular weight of the sequence and one heavy chain N-glycan. Purity was determined based on SE-HPLC. The final protein purity was analyzed based on the SE-HPLC method set on the Agilent LC 1100 / 1200 system and using a BIOSep-SEC-S3000 300 × 7.8 mm column (Phenomenex, catalog number 00H-2146-K0) and a running buffer composed of 200 mM sodium phosphate pH 6.9, 300 mM NaCl and 10% isopropanol. UV280 and fluorescence (Ex280nm / Em 354nm) detectors were used for detection. The antibodies eluted as a single symmetrical peak with a retention time that reflected the size of the antibody. The purity estimates for the different antibodies were all between 95-99%. To determine the final protein concentration, a NanoDrop spectrophotometer (Thermo Scientific) was used along with the specific extinction coefficient for each antibody.
[0757] Example 4: Binning of anti-FIXa stimulatory antibodies
[0758] Antibodies selected as being able to stimulate the enzymatic activity of FIXa towards FX were analyzed in binning experiments to determine the binding characteristics of the identified antibodies using the methods described below.
[0759] Antibody binning method
[0760] The binning experiment was performed using an Octetfortebio system (HTX, Red384) equipped with an anti-human IgG sensor (Pall Life Sciences, Menlo Park, CA) and using 8 or 32 channel mode (Red384 and HTX). The binning experiment was performed using a classic sandwich epitope binning setup. Briefly, (1) the first antibody was captured by an anti-human AHC tip (anti-human IgG Fc capture tip (AHC part number: 18-5064), (2) the unblocked IgG binding site on the AHC tip was blocked with human polyclonal IgG (I4506SIGMA), (3) FIXa was allowed to bind to the first antibody, (4) a competing antibody was provided to the antibody-antigen complex on the tip, and if no binding of the second antibody was detected, the antibodies were scored as belonging to the same bin.
[0761] This analysis identified two distinct bins, bins 1 and 2, defined by antibodies mAb0-1886 and mAb1-1307, respectively.
[0762] Binning of anti-FIX antibodies
[0763] Selected anti-FIX antibodies were binned relative to each other and two different bins were identified (bins 1 and 2). Numbers refer to mAb IDs, e.g. 0-1998 refers to mAb 0-1998.
[0764]
[0765]
[0766] This overview shows that several antibodies were found to belong to bin 1, including mAb0-1886 and mAb0-1998. Bin 2 was found to include four antibodies in addition to mAb1-1307. Two antibodies, mAb1-0072 and mAb1-0073, were common to bins 1 and 2.
[0767] The variants of the parent antibody (repertoire) disclosed herein share bins and epitope (hotspot) residues with the parent antibody
[0768] Since the antibody variants for which data is provided in this example do not contain amino acid substitutions at positions shown to be critical for epitope recognition based on the crystal structure of the parent antibody-FIXa complex provided in Example 5, one skilled in the art will understand that the variants used as a starting point will belong to the same box as the antibodies from which they are derived, i.e., mAb0-1998, mAb0-1886 or mAb1-1307, compete with them for binding, and recognize at least the same hot spot residues in the FIX / FIXa epitope.
[0769] Example 5: Crystallization and epitope mapping of anti-FIX / FIXa antibodies using X-ray crystallography
[0770] The FIXa protein used for crystallization (Cambridge ProteinWorks, product code 10316) consists of a truncated light chain (residues 85-142 of SEQ ID NO: 1) and a heavy chain containing residues 181-415 of SEQ ID NO: 1, which has a non-native methionine residue attached to the N-terminus due to bacterial expression. EGR-chloromethylketone blocks the active site of the protease.
[0771] crystallization
[0772] Fab0-7237: FIXa
[0773] Crystals of Fab0-7237 (corresponding to the Fab fragment of mAb0-1886) mixed with FIXa protein at a 1:1 molar ratio were grown at 18°C using the hanging drop vapor diffusion technique. 0.8 μl of 7.5 mg / ml FIXa was added to 20 mM Tris-HCl, pH 7.4, 50 mM NaCl and 2.5 mM CaCl. 2 The protein solution in was mixed with an equal volume of 4 M sodium formate as a precipitant and incubated on 1 ml of the precipitant.
[0774] Fab0-7238:FIXa
[0775] Crystals of Fab0-7238 (the Fab fragment corresponding to mAb0-1998) mixed with FIXa protein at a 1:1 molar ratio were grown at 18°C using the sitting drop vapor diffusion technique. 0.1 μl of 6.2 mg / ml FIXa was added to 20 mM Tris-HCl, pH 7.4, 50 mM NaCl and 2.5 mM CaCl. 2 The protein solution in 4% MgCl was mixed with 0.1 μl of 100 mM sodium cacodylate, pH 6.5 and 1 M trisodium citrate as precipitants and incubated on 60 μl of precipitant.
[0776] Fab0-7236: FIXa
[0777] Crystals of Fab0-7236 (corresponding to the Fab fragment of mAb1-1307) mixed with FIXa protein at a 1:1 molar ratio were grown at 18°C using the falling drop vapor diffusion technique. 0.1 μl of 6.4 mg / ml FIXa was added to 20 mM Tris-HCl, pH 7.4, 50 mM NaCl and 2.5 mM CaCl. 2 The protein solution in was mixed with an equal volume of 0.2 M lithium sulfate, 40 (v / v)% PEG400 and 0.1 M Tris pH 8.5 as precipitant and incubated on 1 ml of the precipitant.
[0778] Diffraction data collection
[0779] Fab0-7237: FIXa
[0780] Crystals were cryoprotected in a solution consisting of 3 M sodium formate, 4% glycerol, 4% ethylene glycol, 4.5% sucrose and 1% glucose before rapid cooling in liquid nitrogen. The crystals were analyzed at SwissLight Source beamline X06DA ( Diffraction data were collected at 100 K at 400 nm (100 nm wavelength). Automatic indexing, integration and scaling of the data were performed using programs from the XDS package (the diffraction data statistics are summarized in Table 1).
[0781] Fab0-7238:FIXa
[0782] Crystals were cryoprotected in a solution consisting of 75 mM sodium cacodylate, pH 6.5, and 0.75 M trisodium citrate, 4% glycerol, 4% ethylene glycol, 4.5% sucrose, and 1% glucose before rapid cooling in liquid nitrogen. The crystals were imaged at the Swiss Light Source beamline X06DA ( Diffraction data were collected at 100 K at 400 nm (100 nm wavelength). Automatic indexing, integration and scaling of the data were performed using programs from the XDS package (the diffraction data statistics are summarized in Table 1).
[0783] Fab0-7236: FIXa
[0784] The three crystals were cryoprotected in a solution consisting of 0.15 M lithium sulfate, 30 (v / v)% PEG400 and 0.075 M Tris pH 8.5, 4% glycerol, 4% ethylene glycol, 4.5% sucrose and 1% glucose before rapid cooling in liquid nitrogen. The crystals were obtained at the Swiss Light Source beamline X06DA ( Diffraction data were collected at 100 K at 400 nm (100 nm wavelength). Automatic indexing, integration, merging and scaling of the data were performed using programs from the XDS package (the diffraction data statistics are summarized in Table 1).
[0785] Structure determination and refinement
[0786] Fab0-7237: FIXa
[0787] The structure was determined by molecular replacement using Phaser as implemented in the program suite Phenix with the H and L chains of Protein Data Bank entry 4NP4 and the H and L chains from Protein Data Bank entry 3KCG. The asymmetric unit contains two Fab:FIXa complexes. The model was refined using Phenix refinement and a manual rebuilding step in COOT. Refinement statistics are shown in Table 1. Fab0-7238:FIXa
[0788] Phaser as implemented in the program suite Phenix was used to determine the structure by molecular replacement with the H and L chains of protein database entry 4PUB and the H and L chains from protein database entry 3KCG. The asymmetric unit contains two Fab: FIXa complexes. The model was refined using the manual reconstruction step in Phenix refinement and COOT. Refinement statistics are shown in Table 1.
[0789] Fab0-7236: FIXa
[0790] Use Phaser as implemented in program suite Phenix, with the Fab part of the complex structure of above-mentioned Fab0-7238:FIXa complex and H and L chain from protein database entry 3KCG to determine structure by molecular replacement.Asymmetric unit contains a Fab:FIXa complex.This model is refined using Phenix refinement and the manual reconstruction step in COOT.Refinement statistics are shown in Table 1.
[0791] Table 1 - Data collection and refinement statistics
[0792]
[0793]
[0794] Statistics for the highest resolution shell are shown in parentheses.
[0795] Epitope determination
[0796] Based on the above, mAb0-1998, mAb1-1307, and mAb0-1886 were found to bind to different epitopes on FIXa, where an epitope is defined as a distance from a heavy atom in the antibody residues with at least one heavy atom within a distance of .
[0797] The mAb0-1998 epitope is located in the 170-loop and contains the following residues in the protease domain: L337, R338, S339, T340, K341, and T343.
[0798] The mAb1-1307 epitope includes the following residues: H256, H257, N258, K293, R403, Y404, N406, W407, E410, and K411.
[0799] The mAb0-1886 epitope is located in the 170-helix and contains the following residues in the protease domain: K301, D332, R333, A334, T335, R338, and N346.
[0800] The epitopes of mAb0-1998 and mAb0-1886 were found to overlap, which is in good agreement with the observation that these two antibodies compete for binding to FIX / FIXa (Example 4).
[0801] The variants of the parent antibody (repertoire) disclosed herein share bins and epitope (hotspot) residues with the parent antibody
[0802] Since the antibody variants for which data is provided in Example 4 above and certain of the following Examples do not contain amino acid substitutions at positions shown to be critical for epitope recognition based on the crystal structure of the parent antibody-FIXa complex provided in this Example, one skilled in the art will understand that the variants used as a starting point will belong to the same box as the antibodies from which they are derived, i.e., mAb0-1998, mAb0-1886 or mAb1-1307, compete for binding therewith, and recognize at least the same hotspot residues in the FIX / FIXa epitope.
[0803] Example 6: Activity of bivalent anti-FIX / FIXa antibodies in the FXa generation assay
[0804] According to the principle described by Scheiflinger et al. (2008) J Thromb Haemost, 6:315-322, the stimulating effect of bivalent anti-FIX / FIXa antibodies on the enzymatic activity of FIXa against FX was determined by its ability to promote FIXa to activate FX in the presence of procoagulant phospholipid membranes. In view of the high activity of anti-FIXa antibody 224F3 in the antibodies identified by Scheiflinger et al., 224F3 was selected as a reference in the following experiments (for information on the construction of 224F3, see Example 1).
[0805] Anti-FIXa antibodies were measured in an automated high throughput biochemical assay in 384 well plates for the stimulation of FIXa-mediated FX to FXa activation. In brief, FIXa was mixed with purified antibodies at four points, 5 times of dose-response. FX / phospholipid (PL) mixtures were added, FXa was measured by adding FXa substrate (Pefaflour) to generate, and substrate hydrolysis rate was determined by detecting fluorescence on a multi-label reader (PheraSTAR) for 5 minutes. Relative FIXa stimulating activity was calculated as the FXa generation rate from FIXa-antibody complexes compared to independent FIXa.
[0806] The assay was performed by incubating the cells with 3 nM human plasma-derived FIXa (Haematologic Technologies Inc, USA) and 10 μM 25:75 phosphatidylserine:phosphatidylcholine phospholipid vesicles (Haematologic Technologies Inc, USA) in an assay buffer (50 mM HEPES, 100 mM NaCl, 5 mM CaCl 2, 0.1% (w / v) PEG8000, pH 7.3+1mg / ml BSA) in pre-incubation 10 minutes, then add FX (Haematologic Technologies Inc, USA) of human plasma origin to the concentration of 150nM, test each antibody in the concentration range of 0-200nM.After activating at room temperature for 10min, by adding 25μl quenching buffer (50mM HEPES, 100mM NaCl, 60mM EDTA, 0.1% PEG8000, pH 7.3+1mg / ml BSA) quenching reaction (50μl).Then by adding 25μl 2mM S-2765 chromogenic substrate (Chromogenix, Sweden) and by measuring the absorbance (ΔOD / min) at 405nm in a microplate reader, the amount of FXa generated is determined by measuring the chromogenic substrate conversion. The rate of FXa generation at each antibody concentration was determined from a standard curve prepared with known amounts of human plasma-derived FXa (Haematologic Technologies Inc, USA).
[0807] Table 2 lists the measured FXa generation rate of each antibody at the test concentration. Thus, the peak stimulation activity of each antibody was calculated as the maximum FXa generation rate observed relative to 224F3. The data are shown in Table 3, which shows that antibodies belonging to each of the three families (respectively 0-1886, 0-1998 and 1-1307) have an activity that is 10-67 times that observed for 224F3 (Scheiflinger et al.).
[0808] Table 2 - FXa generation rate
[0809] FXa production rate in pM / min (mean ± SD, n=2) for the listed anti-FIX / FIXa antibodies. Each antibody was tested in a concentration range of 0-200 nM as indicated in the first column.
[0810]
[0811] Table 3 - Peak Stimulating Activity
[0812] Peak stimulatory activity of anti-FIX / FIXa antibodies relative to 224F3 (Scheiflinger et al.) in the FXa production assay (mean ± SD, n = 2).
[0813]
[0814] Example 7: Preparation of monovalent (single-arm) antibodies
[0815] To avoid any potential avidity effects associated with conventional monospecific and bivalent antibodies, for example, in the FXa generation assay (Example 8) and certain SPR experiments (Examples 14 and 15), a monovalent one-armed (OA) antibody format was used, as described in Martens et al.: A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivo. Clin. Cancer Res. 12, 6144-6152 (2006), in which a complete heavy chain, a truncated heavy chain (lacking the Fab region), and a light chain were co-expressed. Rather than co-expressing the three chains described by Martens et al., the present invention uses a monovalent one-armed (OA) antibody format as described for bispecific antibodies (Example 10). Principle Preparation of monovalent antibodies. Therefore, monovalent antibodies are prepared by mixing intact monospecific and bivalent antibodies and truncated heavy chain dimers (formally derived from intact antibodies by removing the Fab region) and allowing chain exchange to proceed under the same experimental conditions as described in Example 10. The formation of monovalent antibodies requires that the antibody and the truncated heavy chain dimer carry appropriate complementary mutations to promote heterodimerization, i.e., F405L / K409R for IgG1 and F405L+R409K / WT for IgG4, as described in Example 10.
[0816] In the case of a monovalent antibody of the IgG1 subtype, the truncation of the heavy chain may be from the N-terminus to a position between Cys 220 and the upper hinge Cys 226 (EU numbering). A specific example of a truncated IgG1 heavy chain is an IgG1 heavy chain in which residues 1-220 are truncated.
[0817] In the case of a monovalent antibody of the IgG4 subtype, the truncation of the heavy chain may be from the N-terminus to a position between Cys 200 and the upper hinge Cys 226 (EU numbering). A specific example of a truncated IgG4 heavy chain is an IgG4 heavy chain in which residues 1-214 are truncated.
[0818] Example 8: Activity of monovalent anti-FIX / FIXa antibodies in the FXa generation assay
[0819] In order to avoid any potential avidity effects due to the bivalency of conventional antibody formats, the stimulatory activity of anti-FIX / FIXa antibodies for the enzymatic activity of FIXa against FX was determined after reformatting into a monovalent one-arm (OA) antibody format (see Example 8). The antibodies tested are listed in Table 4 below. The monovalent OA format of the anti-FIXa antibody 224F3 (denoted as mAb1-1582) also mentioned in Example 7 was included for comparison.
[0820] The cells were assayed in an assay buffer (50 mM HEPES, 100 mM NaCl, 5 mM CaCl) at fixed concentrations of phosphatidylserine (PS):phosphatidylcholine (PC) phospholipid vesicles (final concentration 500 μM; Haematologic Technologies Inc, USA) and plasma-derived FIXa (final concentration 0.17, 0.5, or 1 nM; Haematologic Technologies Inc, USA). 2 The stimulatory activity of OA antibodies was determined in 1% (w / v) PEG8000, pH 7.3+1 mg / ml BSA). The concentration of FIXa was selected to ensure that less than 15% of the substrate FX was converted to FXa. After pre-incubation in the presence of monovalent OA antibodies (final concentrations listed in Table 1), 150 nM plasma-derived FX was added to reach a final reaction volume of 50 μl, and activation was performed at room temperature for 20 min. The reaction was then quenched by adding 25 μl of quenching buffer (50 mM HEPES, 100 mM NaCl, 60 mM EDTA, 0.1% PEG8000, pH 7.3+1 mg / ml BSA), and the amount of FXa generated was determined by further adding 25 μl of 2 mM S-2765 chromogenic substrate (Chromogenix, Sweden) and measuring the chromogenic substrate conversion by absorbance measurement (ΔOD / min) at 405 nm in a microplate reader. The measured activity was corrected for background activity by subtracting the signal measured in an identical assay except that FIXa and antibody were replaced with assay buffer, and then the activity was corrected for background activity according to the concentration of FIXa present in the assay ([FIXa] 总 This value was divided by the similarly normalized FXa production rate in the absence of antibody (A FIXa,norm ), calculate the antibody stimulation index, provide the antibody at the concentration used to stimulate the FIXa activity multiple. Because free FIXa produces FXa slowly, the activation reaction in the absence of antibody is performed as described above, but there are 5, 10 or 20nM FIXa. The measured activity is then background subtracted and normalized according to the FIXa concentration in the test. To calculate the stimulation index, the average value of the three normalized activities of free FIXa is used.
[0821] Determination of the stimulation index
[0822] In summary, the calculation of the stimulation index can be described as follows
[0823] Stimulation index = ((A FIXa+OA –A 背景 ) / [FIXa] 总 ) / A FIXa,norm
[0824] Among them A FIXa+OA is the activity measured in the presence of OA antibodies, A 背景 is the background activity measured in the absence of FIXa and monovalent antibody, [FIXa] 总 is the FIXa concentration in this assay, and A FIXa,norm is the mean normalized activity of free FIXa.
[0825] Determination of FIXa saturation
[0826] The fraction of FIXa that is saturated with OA antibody in this assay is determined by the concentrations of FIXa and OA antibody and the equilibrium dissociation constant (K) that governs their interaction. d The latter can be measured by techniques known in the art such as isothermal titration calorimetry (ITC).
[0827] Since the stimulation index will increase with increasing OA antibody concentration until FIXa saturation is reached, the concentration of OA antibody in this assay should be selected to ensure at least 80% saturation of FIXa in the assay to provide an appropriate estimate of the stimulation index at complete FIXa saturation.
[0828] The fraction of FIXa bound to OA antibody at equilibrium (f FIXa+OA ) can be obtained from this assay using the quadratic binding equation as described by Krishnaswamy et al. (1992) J. Biol. Chem., 267: 23696-23706 and detailed in Equations 1 and 2 below. 总 ) and OA([OA] 总 ) and the equilibrium dissociation constant (K d ) is used to calculate, in which [FIXa+OA] 试验 represents the calculated concentration of FIXa-OA antibody complex at equilibrium in the assay
[0829] f FIXa+OA represents the calculated fraction of FIXa bound to the OA antibody at equilibrium in the assay (expressed as a percentage)
[0830] Equation 1:
[0831]
[0832] Equation 2:
[0833]
[0834] The stimulation index for each monovalent OA antibody is provided in Table 4. For all antibodies tested, the stimulation index measured was found to be higher than that measured for the monovalent one-armed 224F3 antibody (mAb1-1582).
[0835] As reported by Kerschbaumer et al. (US7297336-B2), the concentration of the one-armed 224F3 antibody in the experiment was 3260 nM and the K of interaction with FIXa was d At 0.477 nM, more than 95% of FIXa was bound to the one-armed 224F3 antibody in the assay.
[0836] Table 4 - Stimulation of FIXa activity by monovalent one-armed (OA) anti-FIXa antibodies
[0837] The anti-FIX mAb ID refers to the ID of the antibody used to reformat into the OA format. The columns labeled "OA Antibody Concentration (nM)" and "Stimulation Index" list the concentration of OA antibody used in the assay (nM) and the corresponding stimulation of FIXa activity measured relative to free FIXa.
[0838]
[0839]
[0840] Example 9: Development of anti-FX / FXa Fab and mAb expression plasmids
[0841] Anti-FX / FXa antibodies as disclosed herein were developed using standard antibody development methods, and expression plasmids were prepared as described for anti-FIX / FIXa Fab and mAb expression plasmids in Example 1. Expression, purification and characterization of anti-FX / Xa antibodies were also performed as described for anti-FIX / FIXa antibodies in Examples 2 and 3.
[0842] Example 10: Bispecific Antibodies Prepared by In Vitro Assembly
[0843] For bispecific IgG1 antibodies described by (Labrijn et al. PNAS 2013, vol. 110, pp. 5145–5150) Method (Genmab), whereas slightly modified variants were used for the bispecific IgG4 antibody, bispecific antibodies were generated by in vitro assembly of the first and second antibodies, as described in detail below.
[0844] For IgG1, the heavy chain constant region of the first antibody is IgG1K409R (anti-FIX / FIXa) and the heavy chain constant region of the second antibody is IgG1F405L (anti-FX / FXa). As mentioned above, the IgG1 may be an IgG1 variant with reduced effector function.
[0845] For IgG4, the heavy chain constant region of the first antibody is IgG4S228P (anti-FIX / FIXa), and the heavy chain constant region of the second antibody is IgG4S228P F405L R409K (anti-FX). These two parent antibodies were produced as described in Examples 1-3. The Fab arm exchange reaction was carried out in HEPES buffer (pH 7.4) under reducing conditions using 75mM 2-mercaptoethylamine (2-MEA) and incubated at 30°C for 3 hours.
[0846] Example 11: Procoagulant activity of bispecific antibodies
[0847] Through the above Technology Anti-FIXa and anti-hFX antibody pairs were made into bispecific antibodies (Example 10). These bispecific antibodies were tested for procoagulant activity in various assays such as the FXa generation assay described above (Example 6) and the thrombin generation assay (TGT) described in the following paragraph.
[0848] Thrombin generation test (TGT) analysis
[0849] TGT is carried out (HaemoneticsCorporation, #6300) under the automation HTP 384 holes using kaolin triggering are set.In brief, antibody is added (except the mAbi-1371 added with 55nM and the mAbi-0021 added with 166nM) to hemophilia A (HA) plasma (George King) with the concentration of 111nM.Then kaolin (Rossix, #PL604T) mixed with phospholipid is added, and FIIa substrate (FluCa, Thrombinoscope, #TS50.00) is subsequently added.On Perkin Elmer EnVision multi-label plate reader, fluorescence is measured at intervals of 1 minute for 2 hours.Peak height is calculated as the maximum value observed in coagulation figure (thrombogram), then normalized relative to the peak height observed with reference to anti-FIXa and anti-FX antibody. The reference antibody always includes the binding domain from the anti-FX antibody mAb1-2375 (represented by SEQ ID NOs: 93 and 94) in combination with a FIX domain from each of the three families (represented by mAb1-4707, mAb1-5788 and mAb1-4857). According to their relative TGT activity, the antibodies were grouped as low (0-24%), + (24-50%), ++ (50-75%) and +++ (>75%), where + is preferred, ++ is more preferred and +++ is most preferred.
[0850] Selection of preferred combinations of bispecific anti-FIXa / anti-FX antibodies
[0851] A number of anti-FX antibodies were tested as bispecific antibodies in combination with anti-FIXa antibody variants belonging to three lineages: mAbl-1307, mAb0-1886 and mAb0-1998. Selected combinations of anti-FIXa / anti-FX pairs showing significant activity in the TGT assay are shown in Table 5.
[0852] Table 5 - Procoagulant activity of bispecific antibodies
[0853] Selected anti-FIXa / anti-FX bispecific antibody pairs are listed together with their activity in the TGT assay (described above). The bispecific antibodies (Duobodies) were of IgG4 subtype, except mAb 1-0021, mAb 1-1335 and mAb 1-0985, which were IgG1.
[0854]
[0855]
[0856]
[0857] It is apparent from Table 5 that the level of activity exhibited by the bispecific antibodies depends on the specific anti-FIXa / anti-FX combination. For example, the anti-FX antibody mAb1-6723 exhibited strong activity (+++) in combination with the anti-FIXa antibody mAb0-1998, while the activity of mAb1-6723 was lower when combined with mAb0-1886 (+) and mAb1-1307 (+).
[0858] Example 12: Binning of anti-FX antibodies
[0859] Certain anti-FX antibodies that showed significant TGT activity in a bispecific antibody format in combination with an anti-hFIXa antibody (Example 11) were binned relative to each other using the Octet fortebio system using the same setup as described for the anti-FIXa antibody (Example 4), except that FX was used instead of FIXa.
[0860] This analysis identified five distinct bins, bins AE, defined by antibodies mAb1-1371, mAb1-1376, mAb1-6723, mAb1-7447, and mAb1-7449, respectively. Two bins, bin A and bin E, were each represented by only a single anti-FX antibody (see Table 6).
[0861] In box C, a number of clones were identified that competed with mAb 1-6723.
[0862] Table 6 - Binning of anti-FX antibodies
[0863] Selected anti-FX antibodies were binned relative to each other and 5 different bins were identified (bins AE). Numbers refer to antibody IDs, e.g. 1-6723 for mAb 1-6723.
[0864]
[0865]
[0866] Example 13: Crystallization and epitope mapping of anti-FX antibodies using X-ray crystallography
[0867] crystallization
[0868] Crystallization attempts of Fab0-8954 (Fab fragment corresponding to mAb1-6723) in complex with FX were unsuccessful, whereas good quality crystals were obtained in complex with active site inhibited FXa. Therefore, crystals of Fab0-8954 mixed with active site inhibited des-gla FXa (human EGR inhibited factor Xa without gla domain (wild type) bacterial expression, Lot#hGDFXAEGR-022, Cambridge ProteinWorks) in a 1:1 molar ratio were grown at 18°C using the dropping vapor diffusion technique. 150 nl of the 6.7 mg / ml complex was added in 20 mM Tris-HCl (pH 7.4), 50 mM NaCl and 2.5 mM CaCl 2 The protein solution in was mixed with 50 nl of 0.2 M magnesium acetate, 0.1 M sodium cacodylate (pH 6.5), 20% (w / v) PEG 8000 (as precipitant) and incubated on 60 μl of precipitant.
[0869] Diffraction data collection
[0870] Crystals were cryoprotected by adding 1 μl of precipitant with 20% ethylene glycol to the crystallization drop before rapid cooling in liquid nitrogen. The crystals were obtained at the Swiss Light Source beamline X06DA ( Diffraction data were collected at 100 K at 400 nm (100 nm wavelength). Automatic indexing, integration and scaling of the data were performed using programs from the XDS package (the diffraction data statistics are summarized in Table 7).
[0871] Structure determination and refinement
[0872] According to Matthews coefficient analysis, the asymmetric unit contains four Fab:FXa complexes.Structure is determined by molecular replacement.Use Phaser implemented in program suite Phenix, with H and L chains of protein database entry 5I1K as search models for positioning four Fab.These are models that COOT is used to build with correct amino acid sequence, and then refined using Phenix.The refined Fab model is fixed, and molecular replacement is applied as search model using A and B chains from protein database entry 1G2L in Molrep from CCP4 suite simultaneously.Four FXa fragments have been found.This model is refined using the manual reconstruction step in Phenix refinement and COOT.Refinement statistics are shown in Table 7.
[0873] Table 7 - Data collection and refinement statistics
[0874]
[0875]
[0876] Statistics for the highest resolution shell are shown in parentheses.
[0877] Epitope determination
[0878] The crystal structure of the Fab0-8954:FXa complex has four copies of the complex in the asymmetric unit, and these complexes were analyzed separately to use Cut-off distances identify epitopes and paratopes.
[0879] If at least one of the four copies of the Fab0-8954:FXa complex in the unit cell satisfies If the distance standard is used, the residue is included in the epitope for mAb1-6723. The epitope and paratope residues for mAb1-6723 are listed in Table 8.
[0880] Table 8 - Epitopes and paratopes for mAb1-6723
[0881] The epitope residues in the EGF-2 and protease domains of FX / FXa (SEQ ID NO: 2) for mAb 1-6723 are listed in the first and second columns, respectively. H (SEQ ID NO: 21) and V L The paratope residues in (SEQ ID NO: 22) are listed in columns 3 and 4, respectively.
[0882]
[0883]
[0884] The variants of a parent antibody (repertoire) disclosed herein share bins and epitope (hotspot) residues with the parent antibody.
[0885] Since the antibody variants for which data is provided in the Examples do not contain amino acid substitutions at positions shown to be critical for epitope recognition based on the crystal structure of the parent antibody-FXa complex provided in this Example, one skilled in the art will understand that the variants used as a starting point will belong to the same box as the antibody from which they are derived, i.e., mAb1-6723, compete with it for binding, and recognize at least the same hotspot residues in the FX / FXa epitope.
[0886] Example 14: Identification of hotspot residues on FX
[0887] Similar to the mapping of hotspot epitope residues for mAb1-1307, mAb0-1886 and mAb0-1998 on FIX as described in Example 15, the data provided in this example determine the hotspot epitope residues for mAb1-6723 on FX. The FX variant used is a single-site alanine variant of desGla-desEGF1-FX (except position 118, which is alanine in the wild type, in which alanine to serine substitution is introduced), which corresponds to residues 86-448 of SEQ ID NO: 2, with an N-terminal His-tag (HHHHHH, for affinity purification) connected by a short GS-connector (GGGGSGGGGS). Variants covering epitope residues as defined in Example 13 are listed in Table 9.
[0888] Table 9 - List of generated desGla-desEGF1-FX variants
[0889]
[0890]
[0891] 1) According to SEQ ID No:2
[0892] 2) EGF2 and PD refer to the second epidermal growth factor-like and protease domains, respectively.
[0893] Wild-type desGla-desEGF1-FX and variants listed in Table 9 were expressed in the HEK293 system and purified by affinity chromatography. For the L117A, L303A, P304A and M426A variants, no poor expression or purity was observed and it was not possible to assess binding for these four variants.
[0894] The identification of hotspot epitope residues was performed using a Biacore T200 instrument at 25°C. Anti-hIgG Fc antibodies from Human Antibody Capture kit (GE Healthcare, catalog number BR100839) were immobilized on Series S sensor chip CM5 (GE Healthcare, catalog number BR100530) at 2 μg / ml using standard amine coupling chemistry. Anti-FX antibody mAb4-6934 (monovalent variant of mAb1-6723) was injected at a flow rate of 5 μL / min for 30 sec and captured by fixed anti-hIgG Fc antibodies. Subsequently, 5 μM (2- or 3-fold serial dilutions) of T116A, A118S, T127A, F229A and E226A variants, 10 μM (5-fold serial dilutions) of Y230A variant, and 10 μM (2- or 3-fold serial dilutions) of WT and H101A, E103A, R113A, S227A, E228A, R287A, E305A, L419A, K420A, D423A, R424A, K427A and T428A variants were injected at a flow rate of 5 μL / min for 90 sec to allow binding to the captured anti-FX antibody, followed by a 90 sec buffer injection to allow dissociation of the desGLA-desEGF1-FX variants. Running buffer (also used for dilution of anti-FX antibody and desGLA-desEGF1-hFX variant) contained 10 mM HEPES, 150 mM NaCl, 1 mg / mL BSA, and 5 mM CaCl 2 (pH 7.4). 1M formic acid was used to regenerate the sensor chip. According to the 1:1 model in Biacore Evaluation Software 2.0 provided by GE Healthcare, steady-state fitting was used to analyze the binding data. The binding data were reported as the percentage of the binding of FX variants to anti-FX antibodies (monovalent mAb1-6723) relative to the binding of wild-type FX to anti-FX antibodies when 5 or 10 μM FX variants were injected, and calculated according to the following formula:
[0895] Binding (%) = 100% × [(R max_FXvar,Ab ) / (R max_Ab )] / [(R max_FXwt,Ab ) / (R max_Ab )]
[0896] Where R max_Ab represents the capture level of anti-FX antibody (RU), R max_FXvar,Ab and R max_FXwt,AbThe results are shown in Table 10. Table 10 shows the binding (RU) of FX variants and wild type to captured anti-FX antibodies at the same concentration (5 μM except for the Y230A variant, which was 10 μM).
[0897] Table 10 - Results of SPR analysis
[0898] Results from SPR analysis of monovalent variants of mAb 1-6723 binding to selected FX variants covering the epitope residues for mAb 1-6723.
[0899]
[0900]
[0901] Hotspot residues for mAb1-6723
[0902] Hotspot residues for mAb1-6723 were defined as positions at which replacement of the wild-type residue with alanine (or replacement of alanine with serine for position 118) reduced binding of the antibody to 30% or less relative to binding of the antibody to wild-type FX (at a 5 μM concentration of WT (or variant) desGLA-desEGF1-FX).
[0903] Hotspot residues for mAb 1-6723 (represented experimentally by its monovalent counterpart mAb 4-6934):
[0904] R113, Y230, K420, D423, R424 and K427
[0905] Example 15: Identification of hotspot residues on FIX / FIXa
[0906] In order to determine the residues (called hot spots) that are critical for the interaction between anti-FIX / FIXa antibodies mAb0-1886, mAb0-1998 and mAb1-1307 and FIX, a group of FIX variants were selected based on the crystal structure of FIXa complexed with the corresponding Fab fragments (Fab7237, Fab7238 and Fab7236, respectively). As described in detail below, the selected FIX variants were transiently expressed in mammalian cells, purified, and surface plasmon resonance (SPR) was used to characterize their binding to monovalent variants of mAb0-1886, mAb0-1998 and mAb1-1307.
[0907] Generation of FIX mutants
[0908] A DNA plasmid suitable for transient mammalian expression was constructed with an expression cassette encoding amino acid residues 1-461 of human FIX followed directly by six histidines (6×His-tag for affinity purification) (uniprot P00740, corresponding to T148A of SEQ ID NO: 1, except for the T194A mutation according to UNIPROT numbering). The secreted mature FIX protein chain produced using this construct is identical to the A148 allele form of human FIX (Anson et al., EMBO J. 19843: 1053-1060, McGraw et al., Proc Natl Acad Sci USA. 198582: 2847-2851), except for the addition of a C-terminal His tag.
[0909] Using this construct as a template, the selected mutation was introduced by PCR. For each single point mutation listed in Table 11, a forward primer containing the desired amino acid change and a reverse primer containing no amino acid mutation were designed. These primers were used in a standard PCR reaction using the above vector as a template to amplify the entire vector sequence. Using non-ligated cloning, the ends of the resulting amplified DNA fragments were connected to the circular expression plasmid using overlapping sequences introduced by forward and reverse primers.
[0910] The circularized plasmid was transformed into E. coli cells, grown on selective agar plates to form colonies, and the colonies were used to initiate liquid E. coli culture. After overnight growth of E. coli culture, plasmid preparation was performed and mutants were identified by DNA sequencing.
[0911] By using ExpiFectamine TM The Expi293 Expression Kit (ThermoFisher Scientific, catalog number A14525) and plasmid DNA encoding each desired variant as well as wild-type FIX (corresponding to SEQ ID NO: 1 with a C-terminal His-tag) were transfected into the TM Recombinant protein production was performed in expi293F cells grown in suspension culture in culture medium (ThermoFisher Scientific, catalog number A1435101). Vitamin K was added to a final concentration of 5 mg / mL during transfection. The day after transfection, ExpiFectamine TM 293 Transfection Kit Transfection Enhancers 1 and 2. Cell cultures were harvested by centrifugation 5 days after transfection.
[0912] The C-terminal His tag on each FIX variant is used for batch protein purification under the porous robot setting. In brief, the cell culture supernatant of the harvest is adjusted to binding conditions, mixed with Ni Sepharose 6Fast Flow affinity purification resin (GE Healthcare, catalog number 17-5318-02, 50 μl sedimentation resin / ml cell culture medium), and incubated for 20 minutes under shaking. The resin / supernatant mixture is then transferred to the filter plate, and the liquid is sucked through the filter plate by applying vacuum. The resin remaining in the filter plate is washed three times, then eluted in high imidazole buffer.
[0913] Concentration determination of the purified protein solution was performed by ELISA using anti-FIX antibody for detection and highly purified recombinant wild-type FIX for the standard curve.
[0914] Table 11 - List of generated FIX mutants
[0915]
[0916]
[0917]
[0918] 3) According to SEQ ID NO:1
[0919] 4) EGF2 and PD refer to the second epidermal growth factor-like and protease domains, respectively.
[0920] * Variants marked with an asterisk showed very low expression levels and the thermal stability of the FIX variants could not be assessed in binding studies
[0921] To test whether the introduction of amino acid substitutions in FIX variants resulted in destabilization and improper folding, the midpoint of the thermal unfolding transition (T m ).
[0922] The purified FIX variants were loaded into standard capillaries (Prometheus NT.48 nanoDSF Grade Standard capillaries, Nanotemper Technologies GmbH, München) and inserted into Prometheus NT.48 (Nanotemper Technologies GmbH, München). An excitation intensity of 70% was used, and thermal unfolding was performed from 20°C to 90°C with a heating slope of 1.5°C / min. Tryptophan fluorescence was measured by exciting at 280nm and recording the emission at 330nm and 350nm. The T of the FIX variant can be determined from the fluorescence ratio (F350 / 330) measured at 350nm and 330nm. m (This was the case for FIX N101D, H256A, L330A, S339A, G393I, Y404A and N406Q, except when the protein concentration was below 20 μg / ml). In all cases, the program PR.ThermControl v2.0.4 (NanoTemper Technologies GmbH, München) automatically adapted the T by determining the maximum of the first derivative of the F350 / 330 unfolding curve. m . It was found that wild-type FIX T m is 51°C, the T of the variant m In the range of 47 to 54°C, it was shown that the amino acid substitutions did not cause major destabilization.
[0923] SPR analysis
[0924] Using surface plasmon resonance (SPR), the binding of FIX variants to mAb0-1886, mAb0-1998 and mAb1-1307 was characterized by capturing the FIX variants via a C-terminal His-tag. To avoid potential avidity effects associated with conventional bivalent antibodies, i.e., to ensure 1:1 interactions, monovalent variants of mAb0-1886, mAb0-1998 and mAb1-1307, denoted as mAb4-0673, mAb4-0004 and mAb3-3279, respectively (prepared as described in Example 7), were used as analytes.
[0925] SPR analysis was performed on a Biacore 4000 or Biacore T200 instrument (Biacore AB, Uppsala, Sweden). For experiments on a T200 instrument, the following conditions were applied: measurements were performed at a temperature of 25°C. Using standard amine coupling chemistry, 25 μg / ml of anti-His antibody (R&D Systems, catalog number MAB050) was immobilized on a CM5 sensor chip. 25 nM of anti-FIX variants were injected at a flow rate of 10 μl / min for 1 min and captured by the fixed anti-His antibody via its His tag. Subsequently, 200 nM (4-fold serial dilution), 1600 nM (3-fold serial dilution), and 2000 nM (3-fold serial dilution) of mAb4-0004, mAb3-3279, and mAb4-0673 were injected at a flow rate of 50 μl / min for 5 min to allow binding to the captured FIX variants, followed by a 10 min buffer injection to dissociate the monovalent anti-FIX antibodies. The running buffer used was 20 mM Tris, 150 mM NaCl, 5 mM CaCl 2 , 0.05% Tween-20, 1 mg / ml BSA, pH 7.4. It was also used to dilute the anti-FIX antibody and FIX samples. Regeneration of the chip was achieved using 10 mM glycine pH 2.0. Binding data were analyzed according to a 1:1 model using BiaEvaluation 4.1 provided by the manufacturer (Biacore AB, Uppsala, Sweden). A similar experimental setup was used for the Biacore 4000 instrument.
[0926] Initially, all FIX variants listed in Table 11 were screened for binding to all three monovalent antibodies mAb4-0004, mAb3-3279 and mAb4-0673 using a Biacore 4000 instrument. As expected, the binding of antibodies to FIX variants containing mutations at positions corresponding to their respective epitope residues (as defined by the distance criteria outlined in Example 6) was disturbed to varying degrees. For FIX variants containing mutations at positions not corresponding to their respective epitope residues, no significant effects on antibody binding were observed. In particular, the substitutions performed in the EGF2 domain had no effect on binding to any antibody (data not shown).
[0927] A more detailed binding analysis was performed on the residues defined as epitope residues (see Example 6) using a Biacore T200 instrument. The results are given in Table 12.
[0928] Binding data are reported as the percentage of antibody binding to the FIX variant relative to the binding of the antibody to wild-type FIX, which is calculated according to the following formula:
[0929] Binding (%) = 100% × [(R max_Ab,FIX_var ) / (R max_FIXvar )] / [(R max_Ab,FIX_wt ) / (R max_FIXwt )]
[0930] Where R max_FIXvar and R max_FIXwt represents the capture level (RU) of FIX variants and wild-type FIX, respectively, and R max_Ab,FIX_var and R max_Ab,FIX_wt Represents the binding (RU) of the antibodies to the captured FIX variants and wild-type FIX, respectively. The results are shown in Table 12.
[0931] Table 12 - Results of SPR analysis
[0932] Results from SPR analysis of binding of mAb3-3279, mAb4-0004, and mAb4-0673 (monovalent variants of mAb1-1307, mAb0-1998, and mAb0-1886, respectively) to selected FIX variants covering the epitope residues for mAb1-1307, mAb0-1998, and mAb0-1886.
[0933]
[0934]
[0935]
[0936] 1) According to the position of SEQ ID NO:1
[0937] 2) 100% × [(R max_Ab,FIX_var ) / (R max_FIXvar )] / [(R max_Ab,FIX_wt ) / (R max_FIXwt )]
[0938] Hotspot residues mAb1-1307, mAb0-1998 and mAb0-1886
[0939] Hotspot residues for mAbl-1307, mAbO-1998, and mAbO-1886 were defined as positions at which replacement of the wild-type residue with alanine reduced binding of the antibody to 30% or less relative to binding of the antibody to wild-type FX.
[0940] Hotspot residues for mAb1-1307 (represented experimentally by mAb3-3279):
[0941] H257, K293 and N406
[0942] Hotspot residues for mAb0-1998 (experimentally represented by mAb4-0004):
[0943] R338 and K341
[0944] Hotspot residues for mAb0-1886 (experimentally represented by mAb4-0673):
[0945] D332, R333, L337 and R338
[0946] For mAb0-1998 and mAb0-1886, the residue contributing most to binding was R338; replacement of R338 with alanine (R338A) in FIX showed the greatest effect on antibody binding, greatly reducing antibody binding to 2% and 3% for mAb0-1998 and mAb0-1886, respectively, relative to antibody binding to wild-type FIX.
[0947] Example 16: Activity of anti-FIX(a) / FX(a) bispecific antibodies in FXa generation assay
[0948] The procoagulant activity of anti-FIXa / FX bispecific antibodies was determined based on their ability to promote activation of FX by FIXa in the presence of procoagulant phospholipid membranes. The bispecific antibodies (BiAbs) tested are listed in Table 13, and ACE910 was included for comparison.
[0949] The procoagulant activity of each bispecific antibody is reported as the fold stimulation of FX activation relative to free FIXa at a given antibody concentration. The bispecific antibodies were tested at 8 concentrations (prepared by serial three-fold dilution in assay buffer) as follows: with 125 pM human plasma-derived FIXa (Haematologic Technologies Inc, USA) and 500 μM 25:75 phosphatidylserine: phosphatidylcholine phospholipid pre-vesicles (Haematologic Technologies Inc, USA) in assay buffer (50 mM HEPES, 100 mM NaCl, 5 mM CaCl 2, 0.1% (w / v) PEG8000, pH 7.3+1mg / ml BSA) in pre-incubation 10min.Then by adding FX (Haematologic Technologies Inc, USA) to 25nM concentration of human plasma derived activation.After activating at room temperature for 15min, by adding 25μl quenching buffer (50mM HEPES, 100mM NaCl, 60mM EDTA, 0.1% PEG8000, pH 7.3+1mg / ml BSA) quenching reaction (50μl).By adding 25μl 2mM S-2765 chromogenic substrate (Chromogenix, Sweden) and by measuring absorbance (ΔOD / min) at 405nm in microplate reader, measuring chromogenic substrate conversion to measure the amount of FXa generated.Similarly, free FIXa is determined to the activation of FX at 25nM FIXa concentration and 60 minutes reaction time.
[0950] The measured activity was normalized according to the concentration of FIXa present in the assay and the reaction time. The fold stimulation caused by the antibody at a given concentration was calculated by dividing this value by the similarly normalized rate of FXa production in the absence of antibody.
[0951] In summary, the calculation of biAb stimulation can be described as follows:
[0952] BiAb stimulation = (A FIXa+biAb / ([FIXa] 试验 ×t 反应 )) / A FIXa,norm
[0953] Among them A FIXa+biAb is the activity measured in the presence of the bispecific antibody, [FIXa] 试验 is the FIXa concentration in the assay, t 反应 is the reaction time, and A FIXa,norm is the normalized activity of free FIXa.
[0954] Table 13 lists the maximum stimulation measured for each bispecific antibody at the 8 antibody concentrations tested and the concentration at which the maximum stimulation was observed. For all tested bispecific antibodies, the maximum stimulation was found to be higher than the maximum stimulation measured for ACE910, which was tested at a concentration interval of 0 to 15300 nM.
[0955] Table 13 - Maximum stimulation of bispecific anti-FIXa / FX antibodies
[0956]
[0957]
[0958] Example 17: Activity of bispecific anti-FIX(a) / FX(a) antibodies in the thrombin generation assay (TGT) in human hemophilia A platelet-poor and platelet-rich simulated plasma
[0959] The procoagulant activity of bispecific antibodies mAb4-7761, mAb4-7762, mAb4-7789, mAb5-0057 and mAb5-1409 (see Table 14) was determined based on their ability to promote thrombin generation in the presence of procoagulant synthetic phospholipid membranes or platelets according to the principles described by Hemker et al. (Pathophysiol Haemost Thromb, 2002; 32: 249-253). ACE910 was included for comparison. Each antibody (test compound) was tested in a thrombin generation test (TGT) in platelet-poor plasma (HA-PPP) and / or HA-induced human platelet-rich plasma (HA-PRP) from patients with hemophilia A (HA).
[0960] Table 14 - Bispecific anti-FIX(a) / FX(a) antibodies
[0961] BiAb Antibody ID Anti-FIX Antibody ID (Lineage) Anti-FX Antibody ID (Lineage) 4-7761 1-5743(0-1886) 1-6738(1-2375) 4-7762 1-6584(0-1886) 1-6738(1-2375) 4-7789 1-6584(0-1886) 1-6463(1-2375) 5-0057 1-8768(0-1998) 1-6723(1-6723) 5-1409 1-8768(0-1998) 1-7503(1-6723)
[0962] Hemophilia A-induced human platelet-rich plasma (HA-PRP)
[0963] Blood was obtained from healthy donors with informed consent by venipuncture. Six volumes of blood were collected into 1 volume of acid citrate dextrose (ACD; 85 mM sodium citrate, 110 mM dextrose, and 62.3 mM citric acid, pH 4.9), with a final pH of 6.5, and centrifuged at 220 g for 20 min at room temperature (RT). Platelet-rich plasma (PRP) was collected and analyzed using a Medonic CA620 hematology analyzer (Boule Diagnostics AB, Platelet concentration was determined by centrifuging at 600 g for 10 min at room temperature in the plasma fraction containing red blood cells. Platelet-poor plasma (PPP) was collected and used to dilute PRP to 300,000 platelets / μl. HA conditions were induced by adding FVIII neutralizing anti-human FVIII antibody (sheep anti-human factor VIII-5 mg, Haematologic Technologies, VT, USA) to a final concentration of 0.1 mg / ml and gently rotating at 2 rpm for 30 minutes at room temperature.
[0964] Thrombin generation test
[0965] Thrombin generation test (TGT) in HA-PRP and HA-PPP (George King Bio-Medical Inc, KS, USA) was performed by standard calibrated automated thrombography using a 96-well plate fluorimeter (Fluoroscan Ascent FL, Thermolabsystems, Helsinki, Finland). The reaction mixture contained 70 μl of HA-PRP (300,000 platelets / μl) or HA-PPP, 10 μl of test compound dilution (diluted in 20 mM HEPES, 140 mM NaCl, pH 7.4, 2% BSA), 20 μl of CAT reagent (PRP reagent; TF without synthetic phospholipids, PPP reagent LOW; TF with synthetic phospholipids, 1 pM TF final concentration, Thrombinoscope BV, Maastricht, The Netherlands) containing tissue factor (TF) or thrombin calibrator (Thrombinoscope BV), and 20 μl of fluorescently labeled thrombin substrate z-Gly-Gly-Arg-AMC (3 mM) and CaCl 2 The TGT was performed with up to 8 concentrations of the test compound (0.3, 1.0, 3, 10, 30, 100, 300 and 900 nM, final plasma concentration) or with the addition of buffer only (20 mM HEPES, 140 mM NaCl, pH 7.4, 2% BSA) (representing HA control). The concentration range was tested in at least three independent experiments in HA-PPP from the same stock solution or in blood from four different donors. Untreated human PRP or CRYOcheck was used with the addition of buffer only (20 mM HEPES, 140 mM NaCl, pH 7.4, 2% BSA). TM Pooled normal human PPP plasma (Precision Biologic Inc., Dartmouth, Canada) measured normal control levels in TGT. TGT was performed for a total of 90 minutes and the TGT parameter peak thrombin height (nM) was analyzed by Thrombinoscope software (Thrombinoscope BV).
[0966] Figure 2 / Table 15 shows the peak thrombin generation rate measured for each bispecific antibody at the concentration tested in HA-PPP. Data show that all test compounds increase peak thrombin formation to a level higher than that observed in the absence of antibody, i.e., show procoagulant activity. In addition, the thrombin generation level of mAb4-7761, mAb4-7762, mAb4-7789, mAb5-0057 and mAb5-1409 between 30nM and 300nM is higher than the thrombin generation level observed for ACE910, demonstrating excellent efficacy. In addition, the thrombin generation level of mAb5-0057 and mAb5-1409 at 300 to 900nM is higher than the thrombin generation level observed with 900nM ACE910, demonstrating that these compounds have higher efficacy and efficacy compared with ACE910.
[0967] Figure 3 / Table 16 shows the peak thrombin generation levels measured for mAb5-0057 and mAb5-1409 at the concentrations tested in HA-PRP. Under these conditions, mAb5-0057 and mAb5-1409 also exhibited better potency and efficacy compared to ACE910.
[0968] Table 15 - Bispecific antibodies mAb4-7761, mAb4-7762, mAb4-7789, mAb5-0057, mAb5-1409 and Thrombin Generation Test (TGT) of ACE910
[0969] Thrombin generation test (TGT) of bispecific antibodies mAb4-7761, mAb4-7762, mAb4-7789, mAb5-0057, mAb5-1409 and ACE910 in human tissue factor activated hemophilia A platelet-poor plasma (PPP). Average peak thrombin generation level ± standard deviation measured at each test compound concentration in at least three independent experiments in HA-PPP. Experiment AD refers to Figure 2 Independent experiments described in the figure legends.
[0970]
[0971]
[0972] Table 16 - Thrombin generation test (TGT) of bispecific antibodies mAb5-0057, mAb5-1409 and ACE910
[0973] Thrombin generation assay (TGT) of bispecific antibodies mAb5-0057, mAb5-1409 and ACE910 in human tissue factor activated hemophilia A platelet rich plasma (PRP). Mean peak thrombin generation ± standard deviation at each test compound concentration from four independent experiments in HA-PRP.
[0974]
[0975] Example 18: Activity of monovalent one-armed (OA) anti-FIX / FIXa antibodies in the thrombin generation test (TGT) in human hemophilia A platelet-poor plasma
[0976] The procoagulant activity of mAb1-9016 in the form of monovalent single-arm (OA) is determined based on the principle described in Hemker et al. (2002) Pathophysiol Haemost Thromb, 32:249-253 based on its ability to promote thrombin generation in the presence of procoagulant phospholipid membranes. The 224F3 antibody (mAb1-1582) in the form of single-arm is included for comparison. Using 96-well plate fluorometers (Fluoroscan Ascent FL, Thermolabsystems, Helsinki, Finland), the automatic coagulation curve method (thrombography) is calibrated by standard, and each antibody (test compound) is tested in the thrombin generation test (TGT) in the platelet-poor plasma (HA-PPP) (George King Bio-Medical Inc, KS, USA) merged by hemophilia A (HA) patients. The reaction mixture contained 70 μl HA-PPP, 10 μl test compound (diluted in 20 mM HEPES, 140 mM NaCl, pH 7.4, 2% BSA), 20 μl PRP reagent (synthetic phospholipids, Thrombinoscope BV, Maastricht, The Netherlands) containing activated human plasma-derived factor XI (hFXIa, final 8.3 mU / mL) (Enzyme Research Laboratories, IN, USA) or thrombin calibrator (Thrombinoscope BV), and 20 μl containing fluorescently labeled thrombin substrate Z-Gly-Gly-Arg-AMC (3 mM) and CaCl 2 The TGT was performed with a mixture of 100 μg / mL of 1% thrombin and 1% thrombin (90 mM) (Thrombinoscope BV). TGT was performed with five concentrations of test compound (30, 100, 300, 600 and 900 nM, final plasma concentration) or with addition of buffer (20 mM HEPES, 140 mM NaCl, pH 7.4, 2% BSA) (representing HA control). The concentration range was tested in two independent experiments in HA-PPP from the same stock solution. TGT was performed for a total of 90 minutes and the TGT parameter peak thrombin height (nM) was analyzed by Thrombinoscope software (Thrombinoscope BV). Figure 4Table 17 shows / lists the peak thrombin generation rate measured for each monovalent one-armed antibody at the tested concentration. The data show that the OA antibody form of mAb1-9016 increases the peak thrombin formation to a level higher than that observed in the absence of the antibody, i.e., exhibits procoagulant activity. In addition, the thrombin generation induced by the OA antibody form of mAb1-9016 is higher than the thrombin generation observed for the monovalent OA form of the 224F3 antibody (mAb1-1582). Table 17 - Peak thrombin measured for each monovalent one-armed antibody at the concentrations tested Generation speed Mean peak thrombin ± standard deviation of two independent experiments in HA-PPP are shown.
[0977]
[0978] Example 19: Binding affinity determined by isothermal titration calorimetry (ITC)
[0979] The binding affinities of anti-FIX / FIXa and anti-FX / FXa antibodies to FIX / FIXa and FX / FXa, respectively, were measured by isothermal titration calorimetry (ITC) using a PEAQ-ITC calorimeter (Malvern, UK). 2 (Tris-buffer) Experiments were performed at 37°C and pH 7.4. Sample wells (200 μl) contained FIX, FIXa, FX or FXa, and anti-FIX / FIXa and anti-FX / FXa antibodies were injected via syringe. All proteins were fully dialyzed in Tris buffer prior to measurement to ensure that buffer conditions matched. The thermal equilibrium step was followed by a 60-second delay, followed by an initial 0.2-μl antibody injection, followed by 14 injections of 2.5 μl antibody at intervals of 120 s. The stirring speed was maintained at 750 rpm and the reference power was kept constant at 5-10 μcal / s. The heat associated with each antibody injection was integrated and plotted relative to the molar ratio of ligand to macromolecule. The resulting isotherms were fitted to a single-site binding model to obtain affinity (KD), stoichiometry (n) and enthalpy of interaction (ΔH) using software provided by the manufacturer. Experiments were performed in duplicate or triplicate.
[0980] Although certain features of the present invention have been illustrated and described herein, many modifications, substitutions, changes and equivalents will now occur to those skilled in the art. It is therefore to be understood that the appended claims are intended to cover all such modifications and changes that fall within the true spirit of the invention.
Claims
1. A multispecific antibody or antigen-binding fragment thereof capable of stimulating the enzymatic activity of FIXa on FX, comprising a first antigen-binding site capable of binding to FIX (SEQ ID NO: 1) and / or its activated form (FIXa), and a second antigen-binding site capable of binding to FX (SEQ ID NO: 2) and / or its activated form (FXa).
2. The antibody or antigen-binding fragment thereof according to claim 1, wherein the first antigen-binding site is capable of binding to an epitope comprising amino acid residue R338 of FIX / FIXa, and The second antigen binding site is capable of binding in the EGF-2 domain and / or the catalytic subunit of FX / FXa.
3. The antibody or antigen-binding fragment thereof according to claim 1 or 2, wherein the first antigen-binding site is capable of binding to an epitope comprising amino acid residues R338 and K341 of FIX / FIXa.
4. The antibody or antigen-binding fragment thereof according to claim 3, wherein the first antigen-binding site is capable of binding to an epitope comprising amino acid residues L337, R338, S339, T340, K341 and T343 of FIX / FIXa.
5. The antibody or antigen-binding fragment thereof according to claim 1 or 2, wherein the first antigen-binding site is capable of binding to an epitope comprising amino acid residues D332, R333, L337 and R338 of FIX / FIXa, and the second antigen-binding site is capable of binding in the EGF-2 domain and / or catalytic subunit of FX / FXa.
6. The antibody or antigen-binding fragment thereof according to claim 5, wherein the first antigen-binding site is capable of binding to an epitope comprising amino acid residues K301, D332, R333, A334, T335, R338 and N346 of FIX / FIXa.
7. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the second antigen-binding site is capable of binding to an epitope comprising amino acid residues Y230, D423 and K427 of FX / FXa.
8. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the second antigen-binding site is capable of binding to an epitope comprising one or more of amino acid residues H101, E103, R113, T116, L117, A118, T127, S227, E228, F229, Y230, E266, R287, P304, E305, L333, L419, K420, D423, R424, M426, K427 and T428 of FX / FXa.
9. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment thereof competes with a reference antibody for binding to FIX / FIXa, wherein the reference antibody comprises a) a heavy chain variable domain represented by SEQ ID NO: 15 and a light chain variable domain represented by SEQ ID NO: 16, or b) a heavy chain variable domain represented by SEQ ID NO: 17 and a light chain variable domain represented by SEQ ID NO: 18, or c) the heavy chain variable domain represented by SEQ ID NO: 19 and the light chain variable domain represented by SEQ ID NO:
20.
10. The antibody or antigen-binding fragment thereof according to any one of the preceding claims, wherein the antibody or antigen-binding fragment thereof is a bispecific antibody.
11. The antibody or antigen-binding fragment thereof according to claim 1, comprising a. the CDR sequence of the anti-FIX / FIXa antibody heavy chain variable domain represented by SEQ ID NO: 177 and the CDR sequence of the anti-FIX / FIXa antibody light chain variable domain represented by SEQ ID NO: 178, and the CDR sequence of the anti-FX / FXa antibody heavy chain variable domain represented by SEQ ID NO: 179 and the CDR sequence of the anti-FX / FXa antibody light chain variable domain represented by SEQ ID NO: 180, b. the CDR sequence of the anti-FIX / FIXa antibody heavy chain variable domain represented by SEQ ID NO: 181 and the CDR sequence of the anti-FIX / FIXa antibody light chain variable domain represented by SEQ ID NO: 182, and the CDR sequence of the anti-FX / FXa antibody heavy chain variable domain represented by SEQ ID NO: 183 and the CDR sequence of the anti-FX / FXa antibody light chain variable domain represented by SEQ ID NO: 184, c. The CDR sequence of the anti-FIX / FIXa antibody heavy chain variable domain represented by SEQ ID NO: 187 and the CDR sequence of the anti-FIX / FIXa antibody light chain variable domain represented by SEQ ID NO: 188, as well as the CDR sequence of the anti-FX / FXa antibody heavy chain variable domain represented by SEQ ID NO: 185 and the CDR sequence of the anti-FX / FXa antibody light chain variable domain represented by SEQ ID NO:
186.
12. An antibody or antigen-binding fragment thereof according to any one of the preceding claims for use in a method of treating a coagulopathy or coagulation disorder.
13. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof according to any one of the preceding claims for use in the treatment of a coagulopathy or coagulation disorder, such as hemophilia A or hemophilia A with inhibitors.
14. A method of treating a subject having a coagulopathy or coagulation disorder such as hemophilia A or hemophilia A with inhibitors, comprising administering to the subject an antibody or antigen-binding fragment thereof according to any one of the preceding claims.
